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1.INTRODUCTION 
 
 The oral route of drug administration is the most important route of 
administering drugs for systemic effect. About 90% of drugs used to produce systemic 
effects are administered by oral route. When a new drug is discovered one of the first 
questions a pharmaceutist asks is whether or not the drug can be effectively 
administered for its intended effect by the oral route1. 
 
 The drugs that are administered orally, solid oral dosage form represent the 
preferred class of products. The reasons for this preference are as follows. Tablet is unit 
dosage form in which one usual dose of the drug has been accurately placed by 
compression. Liquid oral dosage forms, such as syrups, suspensions, emulsions, 
solutions and elixirs are usually designed to contain one dose of medication in 5 to 30 
ml and the patient is then asked to measure his or her own medication using teaspoons, 
tablespoon or other measuring device. Such dosage measurements are typically in error 
by a factor ranging from 20 to 50% when the drug is self administered by the patient.  
 
1.1 TYPES OF TABLETS 
 A) Tablets ingested orally 3 
 1.  Compressed tablet, e.g. Paracetamol tablet  
  a. Conventional compressed tablet  
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 These tablets are designed to provide rapid disintegration and hence rapid drug 
release and represent significant proportion of tablets that are clinically used. The 
manufacture of this tablet involves the compression of granules or powders (both 
containing the drug) in the required geometry in the ingestion mechanism these tablets 
allows the drug to dissolve into the gastric fluid and disintegrate in the gastro intestinal 
tract (stomach) and finally be absorbed systemically. 
  b. Multiple compressed tablet  
  2.  Repeat action tablets  
  3. Delayed release tablet, e.g. Enteric coated Bisacodyl tablet  
  4. Sugar coated tablet, e.g. Multivitamin tablet  
  5. Film coated tablet, e.g. Metronidazole tablet  
  6. Chewable tablet, e.g. Antacid tablet  
 (B) Tablets used in oral cavity:  
 1. Buccal tablet, e.g. Vitamin-C tablet  
 2. Sublingual tablet, e.g. Vicks Menthol tablet  
 3. Troches or lozenges  
 4. Dental cone  
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 (C) Tablets administered by other route:  
  1. Implantation tablet  
  2. Vaginal tablet, e.g. Clotrimazole tablet  
  (D) Tablets used to prepare solution:  
  1. Effervescent tablet, e.g. Dispirin tablet (Aspirin)  
  2. Dispensing tablet, e.g. Enzyme tablet (Digiplex)  
  3. Hypodermic tablet   
  4. Tablet triturates e.g. Enzyme tablet (Digiplex) 
 
1.1.1 Advantages 2: 
• They are unit dosage forms,  they offer  greatest capabilities of all oral dosage 
forms for the greatest dose precision and the least variability.  
• Their cost is lowest of all oral dosage forms.  
• They are  lightest and the most compact among oral dosage forms.  
• They are in general the easiest and cheapest to package.  
• Product identification is potentially simplest cheapest, requiring no additional 
processing steps when employing and embossed are monogrammed punch face.  
• They may provide the greatest ease of swallowing with the least tendency for 
“hang-up” above the stomach especially when coated provided the tablet 
disintegration is not rapid.  
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• They lend them to certain special release profile products such as enteric or 
delayed release products.  
• They are better suited to large scale production than other unit oral forms.  
 
1.1.2 Disadvantages: 
• Some drugs resist compression into dense compacts, owing to their amorphous 
nature or flocculent, low density character.  
• Drugs with poor wetting, dissolution properties, intermediate to large dosages, 
optimum absorption high in the GIT or any combination of these features may 
be difficult to impossible to formulate and manufacture as a tablet that will still 
provide adequate full drug bioavailability.  
• Bitter tasting drugs, drugs with an objectionable odor or drugs that are sensitive 
to oxygen or atmospheric moisture may require encapsulation or entrapment 
prior to compression or the tablets may require coating. In such cases, the tablets 
may offer the best and lowest cost approach. 
 
1.2 Tablet properties 4: 
 Tablets can be made in virtually any shape, although requirements of patients and 
tableting machines mean that most are round, oval or capsule shaped. More unusual 
shapes have been manufactured but patients find these harder to swallow, and they are 
more vulnerable to chipping or manufacturing problems. 
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 Tablet diameter and shape are determined by the machine tooling used to 
produce them - a die plus an upper and a lower punch are required. This is called a station 
of tooling. The thickness is determined by the amount of tablet material and the position 
of the punches in relation to each other during compression. Once this is done, we can 
measure the corresponding pressure applied during compression. The shorter the distance 
between the punches, thickness and the greater the pressure applied during compression 
and sometimes the harder the tablet. Tablets need to be hard enough that they don't break 
up in the bottle, yet friable enough that they disintegrate in the gastric tract. 
 
 The tablet is composed of the Active Pharmaceutical Ingredient (that is the active 
drug) together with various excipients. These are biologically inert ingredients which 
either enhance the therapeutic effect or are necessary to construct the tablet. The filler or 
diluents (e.g. Lactose or Sorbitol) are a bulking agent, providing a quantity of material 
which can accurately be formed into a tablet. Binders (e.g. methyl cellulose or gelatin) 
hold the ingredients together so that they can form a tablet. Lubricants (e.g. magnesium 
stearate or polyethylene glycol) are added to reduce the friction between the tablet and 
the punches and dies so that the tablet compression and ejection processes are smooth. 
Disintegrants (e.g. starch or cellulose) are used to promote wetting and swelling of the 
tablet so that it breaks up in the gastrointestinal tract; this is necessary to ensure 
dissolution of the API. Super disintegrants are sometimes used to greatly speed up the 
disintegration of the tablet. Additional ingredients may also be added such as coloring 
agents, flavoring agents and coating agents. Formulations are designed using small 
quantities in a laboratory machine called a Powder Compaction Simulator. This can 
prove the manufacturing process and provide information. 
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1.3   CHOICE OF EXCIPIENTS 5: 
 The choice of excipients in tablet formulations depends on the API, the type of 
tablet, the desired characteristics, and the manufacturing process used. Several types of 
tablets are available in the market. These include prompt release, from which the drug 
dissolves in a very short time (sublingual or buccal tablets), and immediate release and 
modified release, which includes most of the oral administered tablets that are swallowed. 
Other types include effervescent, belayed, chewable, multiple compressed topical tablets 
and tablets for solution. The desired characteristics of a tablet may be achieved by adding 
colors, pigments, flavours, sweeteners and a sugar or film coating. The types of 
excipients selected for a formulation depend on the basic process used to manufacture the 
tablets. 
 
1.4 Drug-excipient interactions and their effect on absorption 6: 
  Excipients are traditionally thought of as inert but they can have tremendous 
impact on the ultimate pharmacological availability of a drug substance when added to a 
formulation. The magnitude of this effect will depend on the characteristics of the drug 
and on the quantity and properties of the excipients. Excipients have traditionally been 
classified according to the formulation they perform in a formulation, although many 
excipients perform multiple functions. Diluents allow the formulation of a practically 
sized tablet and can form large proportion by weight of a formulated product when, for 
example, the active ingredient is very potent. The physical characteristics of the diluents 
are important; for example, triamterene was shown to dissolve more rapidly when it was 
formulated with hydrophilic fillers such as lactose and starch as compared with insoluble 
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diluents. Disintegrants tend to swell when wetted and so are added to a formulation to 
facilitate the breakdown of the dosage form into granules and powder particles. The 
newer disintegrants, called superdisintegrants, cause an extremely rapid break up of a 
tablet owing to their ability to swell to many times their original size. Wicking and 
swelling were found to be the primary mechanisms of actions for tablet disintegrants, 
while other mechanisms, such as deformation recovery, particle repulsion theory, heat of 
wetting and evolution of a gas etc., may play a role in particular cases of tablet 
disintegration (kanig and Rudnic,1984). Co processing is defined as combining or more 
established excipients by an appropriate. Co processing of excipient could lead to 
formation of excipients with superior properties compared with the simple physical 
mixtures of their   components or with individual components. A large number of co 
processed diluents are commercially available. The representative examples are 
Ludipress, Cellactose and starlac. The use of co processing is totally unexplored avenues 
in disintegrants. The widely used super disintegrants are SSG, crospovidone and 
croscaramellose sodium. Like diluents each super disintegrants have strengths and 
weakness.  
1.5 Excipients used in tablets 7: 
 Excipients are inert substances used as diluents or vehicles for a drug. In the 
pharmaceutical industry it is a catch all terms which includes various sub-groups. 
Comprising diluents or fillers, binders or adhesives, disintegrants, lubricants, glidants or 
flavours, fragrances and sweeteners. All of these must meet certain criteria as follows:-  
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1. They must be physiological inert. 
2. They must be acceptable to regulatory agencies 
3. They must be physiologically and chemically stable. 
4. They must be free of any bacteria considered to be pathogenic or otherwise 
objectionable. 
5. They must not interfere with the bioavailability of the drug. 
6. They must be commercially available in the form and purity commensurate to 
pharmaceutical standards. 
7. Cost must be relatively inexpensive. 
8. They must conform to all current regulatory requirements. 
 To assure that no excipient interferences with the utilization of the drug, the 
formulator must carefully and critically evaluate combinations of the drug with each of 
the contemplated excipients and must ascertain compliance of each ingredient with 
existing standards and regulations. 
 The screening of drug-excipients and excipient-excipient interactions should be 
carried out routinely in preformulation studies. 
1.5.1 Fillers: (Diluents)  
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 Tablet fillers of comprise a heterogeneous group of substances. Since they often 
comprise the bulk of the tablet, selection of a candidate from this group as a carrier for a 
drug is of prime importance.  
1.5.2 Binders: 
 Binders are the glue that holds powders together to form granules. They are the 
adhesives that are added to tablet formulations to provide the cohesiveness required for 
that bonding together of the granules under compaction to form a tablet. The quantity 
used and the method of application must be carefully regulated, since the tablet must 
remain intact when swallowed and then release its medicament. 
Binders are either sugar or polymeric materials. The latter fall into two classes: 
• Natural polymers such as starches or gums include acacia, tragacanth and 
gelatin. 
• Synthetic polymers such as polyvinylpyrrolidine, methyl and ethyl 
cellulose and hydroxyl propyl cellulose. Binders of both types may be 
added to the powder mix and the mixture wetted with water, alcohol–
water mixtures or a solvent, or binder may be put into solution in the 
water or solvent and added to the powder. The latter method using the 
solution of the binder requires much less binding material to achieve the 
same hardness than if added dry.  
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• Commonly used binders are gelatin, glucose, methyl cellulose, acacia, 
starch paste, povidone, alcohol, PVP in water,  PVP in alcohol and 
sorbitol in water 
 
1.5.3 Lubricants: 
 Lubricants are used in tablet formulation to ease the ejection of the tablet from 
the die, to prevent sticking of tablets to the punches, and to prevent excessive wear on 
punches and dies. They function by interposing a film of low shear strength at the 
interface between the tablet and the die wall and the punch face. Lubricants should be 
carefully selected for efficiency and for the properties of the tablet formulation. 
In selecting a lubricant, the following should be considered: 
1. Lubricants markedly reduce the bonding properties of many 
excipients.  
2. Over blending is one of the main causes of lubrication problems. 
Lubricants should be added last to the granulation and tumble-blended 
for not more than 10 min. 
3. Lubricant efficiency is a function of particle size; therefore, the finest 
grade available should be used and screened through a 100-300 mesh 
screen before use. 
Examples of lubricants commonly used are magnesium stearali acid, talc, 
starch. 
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1.5.4 Disintegrants: 
Disintegrants are used in tablet preparation to break the tablet faster. But some of 
the disintegrants are also having property of enhancing solubility of insoluble drug. 
 
Examples: 
• Crospovidone: Crospovidone is disintegrant, crospovidone also 
enhances solubility. 
• Sodium starch glycollate: sodium starch glycollate is widely used 
in oral pharmaceuticals and as a disintegrant in capsule. 
 
1.5.5 Glidants: 
Glidants are materials that improve the flow characteristics of granules by 
reducingthe inter particulate friction. In proper amounts they also serve to assure smooth 
and uniform flow at all times.  
 Many of the excipients commonly used in tablet formulations are especially 
applicable for use in chewable tablets due to their ability to provide the necessary 
properties of sweetness and chewabilty. In general; these fall into the sugar category, 
although a combination of excipients with artificial sweeteners may provide a satisfactory 
alternative. 
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Uko-Nne and Mendes reported on the development of dried honey and molasses 
products marketed for use in chewable tablets. Both are free-flowing compressible 
materials with characteristics colours, odours and tastes that limit their primary 
applicability to the vitamin/food supplement field. 
 
1.5.6 Super disintegrants in immediate release tablets: 
 A disintegrant is an excipient which is added to a tablet or capsule blend to aid in 
the breakup of the compacted mass when it is put into a fluid environment. This is 
especially important for immediate release products where rapid release of drug 
substance is required. A disintegrant can be added to a powder blend for direct 
compression or encapsulation. It can also be used with products that are wet granulated. 
While there are some tablets fillers (starch, MCC) which aid in disintegration, there are 
more effective agents referred to as superdisintegrants. 
 
1.6 Method of addition of disintegrants : 
The requirement placed on the tablet disintegration should be clearly defined. The 
ideal disintegrant has, 
1. Poor solubility. 
2. Poor gel formation.  
3. Good hydration capacity. 
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4. Good molding and flow properties.  
5. No tendency to form complexes. 
Disintegrants are essentially added to tablet granulation for causing the compressed 
tablet to break or disintegrate when placed in aqueous environment. 
 There are three methods of incorporating disintegrating agents into tablets: 
• Internal addition  
• External addition  
• Partly internal and external 
 In external addition method, the disintegrant is added to the sized granulation 
with mixing prior to compression. In internal addition method, the disintegrant is mixed 
with other powders before wetting the powder mixture with the granulating fluid. Thus 
the disintegrant is incorporated within the granules. When these methods are used part of 
the disintegrants are added internally and part externally. This provides immediate 
dispersion of the tablet into previous compressed granules while the disintegrating agents 
within the granules produce further erosion of the granules to the original powder 
particles. The two stepped method usually produces better and more complete 
disintegration than the usual method of adding the disintegrant to the granulation surface 
only. 
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1.7 Method of preparation of tablet: 
Compressed tablets may be made by three basic methods. 
1. Wet granulation 
2. Direct compression 
3. Slugging 
1.7.1 Wet granulation 8: 
Wet granulation forms the granules by binding the powders together with an adhesive, 
instead of by compaction. The wet granulation technique employs a solution, suspension, 
or slurry containing a binder, which is usually added to the powder mixture; however, the 
binder may be incorporated dry into the powder mix, and the liquid may be added by 
itself. The method of introducing the binder depends on its solubility and on the 
components of the mixture. Since, in general the mass should merely be moist rather than 
wet or pasty, there is a limit to the amount of solvent that may be employed. Therefore, 
when only a small quantity is permissible, the binder is blended in with the dry powders 
initially; when a large quantity is required, the binder is usually dissolved in the liquid. 
The solubility of the binder also has an influence on the choice of methods, since the 
solution should be fluid enough to disperse readily in the mass. The liquid plays a key 
role in the granulation process .liquid bridges are developed between particles, and the 
tensile strength of those bonds increases as the amount of liquid added is increased. 
These surface tension forces and capillary pressure are primarily responsible for initial 
granule formation and strength. Once the granulating liquid has been added, mixing 
continues until a uniform dispersion is attained and all the binder has been activated. 
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During granulation, practices and agglomerates are subjected to consolidating forces by 
action of machine parts and of inter particulate forces.  Granulation in large blenders 
requires 15min to an hour. The length of time depends on the powder mixture and the 
granulating fluid, and upon the efficiency of the mixer. A rough way of determining the 
end point is to press a portion of the mass in the palm of the hand; if the ball crumbles 
under moderate pressure, the mixture is ready for the next stage in processing, which is 
wet screening. Granulation may be considered as a size enlargement process during 
which small particles are formed into larger, physically strong agglomerates in which 
original particles can still be identified. High shear forces in high speed mixers are widely 
used in the pharmaceutical industry for wet granulation. Processing parameters were 
shown to affect the growth rate of granules in the high-shear wet granulation. The main 
objective of granulation is to improve flow properties and compression characteristics of 
the mixture to prevent segregation of the constituents. Though this technique is old for 
the product of compressed tablet, this method is being used because of the content 
uniformity.  
 
Granulation is a process of size enlargement whereby small particles are gathered into 
larger, permanent aggregates in which the original particles can still be identified.1 
The major reason for granulating the powdered starting material in the manufacture of 
tablets and granules are to:  
• To improve the flow properties so that, the mass uniformity of the dose.  
• To prevent segregation of ingredients in the mixture.  
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• To improve the compression characteristics of the mixture.  
• To reduce the environmental hazards for the working personnel due to dust 
formation from toxic materials.  
• To reduce the bulk volume of voluminous powders and make them more 
convenient for storage and transport.  
• To improve the appearance of the product. 
The granules being heavier do not blow out of the die and do not clog the lower 
punch. 
 
                           Rapid mixer granulator (RMG) with impeller and chopper 
 
1.8  Drying 
Drying in the Rapid Dryer makes use of the fluidized bed process, a technique similar to 
the one used in industrial dryers. Ambient air is drawn in through a filter. A blower 
moves the air around the motor and across heating elements, and ultimately forces it 
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through the perforated plate and into the detachable drying container. The solid particles 
are blown upward and agitated and thus kept separate one from another so that their 
surfaces cannot stick together. The air stream extracts moisture from the particles and 
then exits through the filter bag in cover of the drying container. 
 
1.9 Film coating: 
The Film-coating technology has become well established inthe pharmaceutical industry 
and has made great advances. Improved production equipment and the development of 
highly efficient film-coating formulations and polymers have accelerated the acceptance 
of film-coating technologies. 
 
Hydroxypropyl methyl cellulose (HPMC) was typically used in film-coating 
formulations, as a film forming polymer, and remains in common usage. HPMC is 
obtained through a sumptuous serial procedure. Firstly, cellulose is extracted from either 
cotton flock or paper pulp and solubilised in sodium hydroxide solutions to obtain 
swollen cellulose. Hydroxypropyl methyl cellulose is subsequently obtained by treating 
the swollen cellulose with methyl chloride and propylene oxide. Finally the mass is dried, 
comminuted and packaged after removal of dopants. HPMC is typically sold in several 
grades with different viscosities. To realize high solid matter contents HPMC of low 
viscosity is commonly used. Optimized formulations however consist of a combination of 
the different grades to combine their various physical properties. Optimally developed 
formulations could therefore obtain up to 20 percent solid matter content if further 
additives (Eg. sugar alcohols) are added. Since the formulation of those multi component 
systems is quite inconvenient the next generation of film forming polymer came up: 
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polyvinyl alcohol (PVA). PVA is a film-forming agent produced by the hydrolysis of 
polyvinyl acetate. An alkali metal or inorganic acid is used as a catalyst in methanol, 
ethanol or a mixture of ethanol and methyl acetate, to accelerate the hydrolysis of 
polyvinyl acetate to yield polyvinyl alcohol (PVA).Nowadays, PVA is used as film 
forming agent in a number of pharmaceutical formulations. An optimized instant release 
film coating formulation based on PVA, can be applied on the tablets with a solid matter 
content of up to 25 percent, which is a major step towards achieving highly efficient film 
coating processes. Besides the increased solids content of the formulations, other 
properties, like reduced permeability of water vapour or oxygen through a film, have also 
been achieved. Apart from the film forming polymer and pigments, a asticizer is typically 
added to HPMC as well as PVA based formulations. The addition of plasticizer improves 
physical properties like the flexibility of the film, or lowering of the glass transition 
temperature (Tg).However, these plasticizers might migrate in the film and can cause 
stability problems of the film respectively the finished dosage form. The latest generation 
of film coating polymers was developed targeting an improved coating efficiency. An 
example of this new generation is Kollicoat® IR, which is obtained by grafting polyvinyl 
alcohol on a polyethylene glycol backbone. The PEG as covalently bond plasticizer 
prevents the formulation from instability due to migration of the plasticizer through the 
film or incompatibilities with actives. Due to the low viscosity compared to all previous 
film coating materials, formulations based on Kollicoat® IR can be applied in 
concentrations of up to 30 percent. 
 
PEG-PVA grafted polymer formulations are easy to dissolve, form flexible films 
on tablets and have a similar barrier function for water vapour and oxygen as PVA based 
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films. Using these types of polymers for film coating purposes, more convenient and 
more efficient coating formulations have been developed by several suppliers. These 
coating systems are mixtures of film-forming polymers, plasticizers, colour ingagents and 
other excipients, which can be easily stirred into water or organic solvents, to produce the 
dispersion for the film coating of tablets. There are several approaches available in the 
market: (I) HPMC or PVA based coating systems which are often customized powder 
blends for every single finished dosage form (II) The PEG-PVA based systems which are 
sold as a seven base colour system, containing homogeneous granules, which can match 
hundreds of different colours by combining these coloured granules. 
 
Rapid development of film-coating formulations - in order to improve efficiency - and 
the increasing interest in optimization of process times and energy consumption, suggests 
that a comparison of commonly-used coating systems would be in order. 
 
1.9.1 Energy flux in coating process 
The thermodynamic model introduced below, potentially describes the energy flux in a 
model film coating process and helps to provide an understanding of this process.For the 
calculation of the energy flux in a film coating process, the first law of thermodynamics 
can be applied. Since the sum of all energies in a closed system remains the same, the 
total energy can be described as: 
 
Q inlet air = Q heat tablets + Q heat coater + Q heat solution + Q evap. solvent + Q loss + 
Q exhaust air  
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For the film coating process itself various energies are of importance. However, focusing 
on ecological and economical aspects enthalpies derived from atomizing air and 
dispersion can be disregarded, as these energies do not depend on energy consumption of 
heaters. Qinlet air describes the energy introduced into the coating process through the 
heated and conditioned process air. Yet this amount of energy has to be used for any kind 
of economical and ecological considerations, as it represents the main amount of energy, 
introduced in the film coating process. Besides the amount of energy introduced due to 
the inlet air and atomizing air, energy is also required to revolve the coating drum or to 
convey the coating dispersion to the spray nozzles. Due to the fact, that the amount of 
energy for this is minor, compared to the total energy and that the process settings (and 
hence the required energy) is the same in all compared cases, this energy is not 
considered in the calculation of energy savings. 
 
 
Figure–1 Sketch of a typical film coating process and its influencing parameters. 
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1.10 Conventional drug delivery system 14:  
Conventional drug delivery system  is defined as – Conventional release tablets 
are designed to disintegrate and release their medicaments with no special rate controlling 
features such as special coatings and other techniques. 
Conventional drug therapy requires periodic doses of therapeutic agents. These agents are 
formulated to produce maximum stability, activity and bioavailability. For most drugs, 
conventional drug delivery is effective, but some drugs are unstable or toxic and have 
narrow therapeutic window and solubility problems. In such cases, a method of 
continuous administration of therapeutic agent is desirable to maintain fixed plasma 
levels as shown in fig. This continuous drug delivery can be achieved by the use of 
controlled drug delivery systems. These delivery systems have a number of advantages 
over traditional systems such as improved efficiency, reduced toxicity and improved 
patient convenience. The main goal of modified drug delivery systems is to improve the 
effectiveness of drug therapies. 
Conventional dosage forms are rapidly absorbed, with the ascending and descending 
portions of the concentrations versus time curve reflecting primarily the rate of 
absorption and elimination, respectively. Because of the rapid rate of absorption and 
elimination from conventional dosage forms, drugs are usually administered more than 
once daily, with the frequency being dependent on biological half life (t1/2) and duration 
of pharmacological effect. The time of dosing may also be effected by therapeutic index 
of a drug. 
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Figure - 2: Drug plasma levels after oral administration of a drug from an immediate-
release dosage form. The therapeutic range is the concentration interval between the 
minimal effective concentration (MEC) and the minimum toxic concentration (MTC). ∆t 
is the time interval the drug is in the therapeutic range. 
1.10.1  Advantages of conventional drug delivery systems: 
 Release the drug immediately. 
 More flexibility for adjusting the dose. 
 It can be prepared with minimum dose of drug. 
 There is no dose dumping problem. 
 Conventionaldrug delivery systems used in both initial stage and final stage of 
disease. 
 At the particular site of action the drug is released from the system. 
CHAPTER-1                                                                                           INTRODUCTION 
 
Dept. of Pharmaceutics                23                          J.K.K.M.M.R.F college of 
pharmacy 
 
1.10.2. Disadvantages of conventional drug delivery systems  
 In conventional oral drug delivery systems, there is little or no control 
over the release of the drug and effective concentration at the target site. 
 The dosing pattern in conventional dosage forms results in constantly 
changing, unpredictable and often sub-therapeutic plasma concentrations 
leading to marked side effects in some cases. 
 Conventional drug delivery system is not suitable for the drugs which 
cause irritation to the gastric mucosa. 
 
1.11 Hypertension 
Hypertension is a chronic medical condition in which the blood pressure is elevated. It is 
also referred to as high blood pressure or shortened to HT, HTN or HPN. The word 
"hypertension", by itself, normally refers to systemic, arterial hypertension.  
Hypertension can be classified as either essential (primary) or secondary. Essential or 
primary hypertension means that no medical cause can be found to explain the raised 
blood pressure and represents about 90-95% of hypertension cases. Secondary 
hypertension indicates that the high blood pressure is a result of (i.e., secondary to) 
another condition, such as kidney disease or tumours (adrenal adenoma or 
pheochromocytoma). 
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High blood pressure (HBP) or hypertension means high pressure (tension) in the arteries. 
Arteries are vessels that carry blood from the pumping heart to all the tissues and organs 
of the body. High blood pressure does not mean excessive emotional tension, although 
emotional tension and stress can temporarily increase blood pressure. Normal blood 
pressure is below 120/80; blood pressure between 120/80 and 139/89 is called "pre-
hypertension", and a blood pressure of 140/90 or above is considered high. 
The top number, the systolic blood pressure, corresponds to the pressure in the arteries as 
the heart contracts and pumps blood forward into the arteries. The bottom number, the 
diastolic pressure, represents the pressure in the arteries as the heart relaxes after the 
contraction. The diastolic pressure reflects the lowest pressure to which the arteries are 
exposed. 
An elevation of the systolic and/or diastolic blood pressure increases the risk of 
developing heart (cardiac) disease, kidney (renal) disease, hardening of the arteries 
(atherosclerosis or arteriosclerosis), eye damage, and stroke (brain damage). These 
complications of hypertension are often referred to as end-organ damage because damage 
to these organs is the end result of chronic (long duration) high blood pressure. For that 
reason, the diagnosis of high blood pressure is important so efforts can be made to 
normalize blood pressure and prevent complications. 
It was previously thought that rises in diastolic blood pressure were a more important risk 
factor than systolic elevations, but it is now known that in people 50 years or older 
systolic hypertension represents a greater risk. 
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The American Heart Association estimates high blood pressure affects approximately one 
in three adults in the United States - 73 million people. High blood pressure is also 
estimated to affect about two million American teens and children, and the Journal of the 
American Medical Association reports that many are under-diagnosed. Hypertension is 
clearly a major public health problem. 
    
     Figure – 3 Blood pressure in blood vessels 
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Figure – 4 Tension in vessels 
1.11.1 Symptoms 
Uncomplicated high blood pressure usually occurs without any symptoms (silently) and 
so hypertension has been labeled "the silent killer." It is called this because the disease 
can progress to finally develop any one or more of the several potentially fatal 
complications of hypertension such as heart attacks or strokes. Uncomplicated 
hypertension may be present and remain unnoticed for many years, or even decades. This 
happens when there are no symptoms, and those affected fail to undergo periodic blood 
pressure screening. 
 
Some people with uncomplicated hypertension, however, may experience symptoms such 
as headache, dizziness, shortness of breath, and blurred vision. The presence of 
symptoms can be a good thing in that they can prompt people to consult a doctor for 
treatment and make them more compliant in taking their medications. Often, however, a 
person's first contact with a physician may be after significant damage to the end-organs 
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has occurred. In many cases, a person visits or is brought to the doctor or an emergency 
room with a heart attack, stroke, kidney failure, or impaired vision (due to damage to the 
back part of the retina). Greater public awareness and frequent blood pressure screening 
may help to identify patients with undiagnosed high blood pressure before significant 
complications have developed. 
 
About one out of every 100 (1%) people with hypertension is diagnosed with severe high 
blood pressure (accelerated or malignant hypertension) at their first visit to the doctor. In 
these patients, the diastolic blood pressure (the minimum pressure) exceeds 140 mm Hg! 
Affected persons often experience severe headache, nausea, visual symptoms, dizziness, 
and sometimes kidney failure. Malignant hypertension is a medical emergency and 
requires urgent treatment to prevent a stroke (brain damage). 
 
1.11.2 Organ damage due to hypertension 
Damage of organs fed by the circulatory system due to uncontrolled hypertension is 
called end-organ damage. As already mentioned, chronic high blood pressure can lead to 
an enlarged heart, kidney failure, brain or neurological damage, and changes in the retina 
at the back of the eyes. Examination of the eyes in patients with severe hypertension may 
reveal damage; narrowing of the small arteries, small hemorrhages (leaking of blood) in 
the retina, and swelling of the eye nerve. From the amount of damage, the doctor can 
gauge the severity of the hypertension. 
 
People with high blood pressure have an increased stiffness, or resistance, in the 
peripheral arteries throughout the tissues of the body. This increased resistance causes the 
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heart muscle to work harder to pump the blood through these blood vessels. The 
increased workload can put a strain on the heart, which can lead to heart abnormalities 
that are usually first seen as enlarged heart muscle. Enlargement of the heart can be 
evaluated by chest X-ray, electrocardiogram, and most accurately by echocardiography 
(an ultrasound examination of the heart). Echocardiography is especially useful in 
determining the thickness (enlargement) of the left side (the main pumping side) of the 
heart. Heart enlargement may be a forerunner of heart failure, coronary (heart) artery 
disease, and abnormal heart rate or rhythms (cardiac arrhythmias). Proper treatment of 
the high blood pressure and its complications can reverse some of these heart 
abnormalities. 
Blood and urine tests may be helpful in detecting kidney abnormalities in people with 
high blood pressure. (Remember that kidney damage can be the cause or the result of 
hypertension.) Measuring the serumcreatinine in a blood test can assess how well the 
kidneys are functioning. An elevated level of serum creatinine indicates damage to the 
kidney. In addition, the presence of protein in the urine (proteinuria) may reflect chronic 
kidney damage from hypertension, even if the kidney function (as represented by the 
blood creatinine level) is normal. Protein in the urine alone signals the risk of 
deterioration in kidney function if the blood pressure is not controlled. Even small 
amounts of protein (microalbuminuria) may be a signal of impending kidney failure and 
other vascular complications from uncontrolled hypertension. African American patients 
with poorly controlled hypertension are at a higher risk than Caucasians for most end-
organ damage and particularly kidney damage. 
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Uncontrolled hypertension can cause strokes, which can lead to brain or neurological 
damage. The strokes are usually due to a hemorrhage (leaking blood) or a blood clot 
(thrombosis) of the blood vessels that supply blood to the brain. The patient's symptoms 
and signs (findings on physical examination) are evaluated to assess the neurological 
damage. A stroke can cause weakness, tingling, or paralysis of the arms or legs and 
difficulties with speech or vision. Multiple small strokes can lead to dementia (impaired 
intellectual capacity). The best prevention for this complication of hypertension or, for 
that matter, for any of the complications, is control of the blood pressure. Recent studies 
have also suggested the angiotensin receptor blocking drugs may offer an additional 
protective effect against strokes above and beyond control of blood pressure. 
 
1.11.3  High Blood Pressure (Hypertension) At A Glance 
• High blood pressure (hypertension) is designated as either essential (primary) 
hypertension or secondary hypertension and is defined as a consistently elevated 
blood pressure exceeding 140/90 mm Hg.  
• In essential hypertension (95% of people with hypertension), no specific cause is 
found, while secondary hypertension (5% of people with hypertension) is caused 
by an abnormality somewhere in the body, such as in the kidney, adrenal gland, or 
aortic artery.  
CHAPTER-1                                                                                           INTRODUCTION 
 
Dept. of Pharmaceutics                30                          J.K.K.M.M.R.F college of 
pharmacy 
 
• Essential hypertension may run in some families and occurs more often in the 
African American population, although the genes for essential hypertension have 
not yet been identified.  
• High salt intake, obesity, lack of regular exercise, excessive alcohol or coffee 
intake, and smoking may all adversely affect the outlook for the health of an 
individual with hypertension.  
• High blood pressure is called "the silent killer" because it often causes no 
symptoms for many years, even decades, until it finally damages certain critical 
organs.  
• Poorly controlled hypertension ultimately can cause damage to blood vessels in 
the eye, thickening of the heart muscle and heart attacks, hardening of the arteries 
(arteriosclerosis), kidney failure, and strokes.  
• Heightened public awareness and screening of the population are necessary to 
detect hypertension early enough so it can be treated before critical organs are 
damaged. 
• Lifestyle adjustments in diet and exercise and compliance with medication 
regimes are important factors in determining the outcome for people with 
hypertension.  
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• Several classes of anti-hypertensive medications are available, including ACE 
inhibitors, ARB drugs, beta-blockers, diuretics, calcium channel blockers, alpha-
blockers, and peripheral vasodilators.  
• Most antihypertensive medications can be used alone or in combination: some are 
used only in combination; some are preferred over others in certain specific 
medical situations; and some are not to be used (contraindicated) in other 
situations.  
• The goal of therapy for hypertension is to bring the blood pressure down to 
140/85 in the general population and to even lower levels in diabetics, African 
Americans, and people with certain chronic kidney diseases.  
• Screening, diagnosing, treating, and controlling hypertension early in its course 
can significantly reduce the risk of developing strokes, heart attacks, or kidney 
failure. 
 
1.11.4 Causes of Hypertension 
1.11.4.1 Essential hypertension: 
Essential hypertension is the most prevalent hypertension type, affecting 90-95% of 
hypertensive patients Although no direct cause has identified itself, there are many 
factors such as sedentary lifestyle, stress, visceral obesity, potassium deficiency 
(hypokalemia)  obesity (more than 85% of cases occur in those with a body mass index 
greater than 25),[33]salt (sodium) sensitivity, alcohol intake, and vitamin D deficiency. 
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Risk also increases with aging,some inherited genetic mutations and family history. An 
elevation of renin, an enzyme secreted by the kidney, is another risk factor, as is 
sympathetic nervous system overactivity. Insulin resistance which is a component of 
syndrome X, or the metabolic syndrome is also thought to contribute to hypertension. 
Recent studies have implicated low birth weight as a risk factor for adult essential 
hypertension.  
 
  
1.11.6 Treatment of hypertension: 
1. Diuretics: 
Thiazides: Hydrochlorthiazide, Chlorthalidone, Indapamide. 
High ceiling: Furosemide. 
K+sparing: Spiranolactone, Amiloride. 
 
2. ACE inhibitors: 
Captopril, Enalapril, Lisinopril, Perindopril, Ramipril, etc.., 
3. Angiotensin blockers: 
Losartan, Candesartan, Irbesartan, Valsartan, Telmesartan. 
4. Calcium channel blockers: 
Verapamil, Diltiazem etc., 
5. Adrenergic blockers: 
Propanolol, Labetelol, etc., 
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6. Central sympatholytics: 
Clonidine, Methyl dopa. 
7. Vasodilators: 
Arteriolar: Hydralyzine, Minoxidil. 
Arteriolar + Venous: Sodium nitroprusside. 
 
1.11.7  Angiotensin receptor blockers : 
 These are developed as an alternative for ACE inhibitors. Several antagonists of 
AT2 receptors as well as combined AT1 + AT2 antagonists have been produced.  
Pharmacologically these differ from ACE inhibitors in the following ways: 
 They do not interfere with degradation of bradykinin and other ACE substrates. 
No rise in level or potentiation of bradykinin occurs. Consequently, ACE inhibitor related 
cough is rare. 
 They result in more complete inhibition of AT1 receptor activation, because 
alternative pathway of A-II generation and consequent AT1 receptor activation remain 
intact with ACE inhibitors. 
 They result in indirect AT2 receptor activation. Due to blockade of AT1 receptor 
mediated feedback inhibition-more A-II is produced which acts on AT2 receptors that 
remain unblocked. ACE inhibitors result in depression of both AT1 and AT2 activstion. 
1.11.7.1  Mechanism of action 
These substances are AT1-receptor antagonists – that is, they block the activation of 
angiotensin II AT1 receptors. Blockage of AT1 receptors directly causes vasodilation, 
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reduces secretion of vasopressin, and reduces production and secretion of aldosterone, 
amongst other actions. The combined effect reduces blood pressure. 
The specific efficacy of each ARB within this class depends upon a combination of three 
pharmacodynamic and pharmacokinetic parameters. Efficacy requires three key PD/ PK 
areas at an effective level; the parameters of the three characteristics will need to be 
compiled into a table similar to one below, eliminating duplications and arriving at 
consensus values; the latter are at variance now. 
1.11.7.2 Pharmacology 
These drugs have very similar effects to angiotensin converting enzyme (ACE) inhibitors 
and are used for the same indications (hypertension, heart failure, post- myocardial 
infarction). Their mechanism of action, however, is very different from ACE inhibitors, 
which inhibit the formation of angiotensin II. ARBs are receptor antagonists that block 
type 1 angiotensin II (AT1) receptors on bloods vessels and other tissues such as the 
heart. These receptors are coupled to the Gq-protein and IP3 signal transduction pathway 
that stimulates vascular smooth muscle contraction. Because ARBs do not inhibit ACE, 
they do not cause an increase in bradykinin, which contributes to the vasodilation 
produced by ACE inhibitors and also some of the side effects of ACE inhibitors (cough 
and angioedema).  
ARBs have the following actions, which are very similar to ACE inhibitors:  
• Dilate arteries and veins and thereby reduce arterial pressure and preload and 
afterload on the heart. 
• Down regulate sympathetic adrenergic activity by blocking the effects of 
angiotensin II on sympathetic nerve release and reuptake of norepinephrine. 
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• Promote renal excretion of sodium and water (natriuretic and diuretic effects) by 
blocking the effects of angiotensin II in the kidney and by blocking angiotensin II 
stimulation of aldosterone secretion. 
• Inhibit cardiac and vascular remodeling associated with chronic hypertension, 
heart failure, and myocardial infarction. 
1.11.8.3 Uses: 
 The ARBs have the same overall range of clinical utility as ACE inhibitors, but 
the suitability efficacy of one over the other is not clearly defined. It may depend on the 
condition being treated and specific features of the patient. The value of their 
combination versus monotherapy is also still unsettled. 
1.11.8 Diuretics 
1.11.8.1  Mechanisms of diuretic drugs 
Diuretic drugs increase urine output by the kidney (i.e., promote diuresis). This is 
accomplished by altering how the kidney handles sodium. If the kidney excretes more 
sodium, then water excretion will also increase. Most diuretics produce diuresis by 
inhibiting the reabsorption of sodium at different segments of the renal tubular system. 
Sometimes a combination of two diuretics is given because this can be significantly more 
effective than either compound alone (synergistic effect). The reason for this is that one 
nephron segment can compensate for altered sodium reabsorption at another nephron 
segment; therefore, blocking multiple nephron sites significantly enhances efficacy.  
Thiazide diuretics, which are the most commonly used diuretic, inhibit the sodium-
chloride transporter in the distal tubule. Because this transporter normally only reabsorbs 
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about 5% of filtered sodium, these diuretics are less efficacious than loop diuretics in 
producing diuresis and natriuresis. Nevertheless, they are sufficiently powerful to satisfy 
most therapeutic needs requiring a diuretic. Their mechanism depends on renal 
prostaglandin production.  
 
Because loop and thiazide diuretics increase sodium delivery to the distal segment of the 
distal tubule, this increases potassium loss (potentially causing hypokalemia) because the 
increase in distal tubular sodium concentration stimulates the aldosterone-sensitive 
sodium pump to increase sodium reabsorption in exchange for potassium and hydrogen 
ion, which are lost to the urine. The increased hydrogen ion loss can lead to metabolic 
alkalosis. Part of the loss of potassium and hydrogen ion by loop and thiazide diuretics 
results from activation of the renin-angiotensin-aldosterone system that occurs because of 
reduced blood volume and arterial pressure. Increased aldosterone stimulates sodium 
reabsorption and increases potassium and hydrogen ion excretion into the urine.  
There is a third class of diuretic that is referred to as potassium-sparing diuretics. 
Unlike loop and thiazide diuretics, some of these drugs do not act directly on sodium 
transport. Some drugs in this class antagonize the actions of aldosterone (aldosterone 
receptor antagonists) at the distal segment of the distal tubule. This causes more sodium 
(and water) to pass into the collecting duct and be excreted in the urine. They are called 
K+-sparing diuretics because they do not produce hypokalemia like the loop and thiazide 
diuretics. The reason for this is that by inhibiting aldosterone-sensitive sodium 
reabsorption, less potassium and hydrogen ion are exchanged for sodium by this 
transporter and therefore less potassium and hydrogen are lost to the urine. Other 
potassium-sparing diuretics directly inhibit sodium channels associated with the 
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aldosterone-sensitive sodium pump, and therefore have similar effects on potassium and 
hydrogen ion as the aldosterone antagonists. Their mechanism depends on renal 
prostaglandin production.  
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        2. LITERATURE REVIEW 
 
Paul R. Conlin et al., 20 in 2001 Studied the current treatment options for 
hypertension, with particular emphasis on the angiotensin receptor blockers 
(ARBs). Losartan, the most widely studied agent of this class, is also discussed. 
In hypertensive patients, losartan has been compared with other 
antihypertensive agents, including enalapril, amlodipine, and nifedipine 
gastrointestinal therapeutic system. In each case, an antihypertensive regimen 
of losartan once daily with or without hydrochlorothiazide showed 
comparable blood pressure-lowering effects. Losartan has also consistently 
demonstrated an excellent tolerability profile, with an overall incidence of 
adverse effects similar to that of placebo.  
 
Javier dfez et al., in 200621 Studied the Losartan Intervention For Endpoint reduction 
in hypertension (LIFE) study found that a losartan-based regimen, compared with an 
atenolol based regimen, resulted in a significantly lower risk of stroke in hypertensive 
patients with left ventricular hypertrophy, despite similar reductions in blood pressure. 
The purpose of this work was to examine the molecular and pharmacologic 
mechanisms that may be associated with the different outcomes observed in the LIFE 
study. Losartan's significant effect on stroke may be related to several possible 
mechanisms that are independent of blood-pressure reductions. These include 
improvements in endothelial function and vascular structure; decreases in vascular 
oxidative stress; reductions in left ventricular hypertrophy, reductions in myocardial 
fibrosis, or both; and modulation of atherosclerotic disease progression. 
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N.N.RAJENDRAN et al., 22 in 2010 investigated the effect of a novel drug- drug 
solid dispersion approach on the dissolution of hydrochlorothiazide in a fixed dose 
combination with Losartan potassium. Solid dispersion of hydrochlorothiazide and 
losartan potassium (12.5mg: 50mg) was prepared by co-precipitation method. Solid 
dispersions were characterized by differential scanning calorimetry, x-ray 
diffractometry and dissolution tests and the results were compared with that of pure 
drugs and physical mixtures. Solid dispersion as well as physical mixture were then 
compressed into tablets and evaluated for physicochemical, stability and dissolution 
characteristics and the results compared with commercial tablets. Both solid 
dispersion and solid dispersion tablets of hydrochlorothiazide and losartan potassium 
showed an enhanced dissolution of hdrochlorothiazide compared with pure 
hydrochlorothiazide, physical mixture, and commercial tablets. The solubility of 
hydrochlorothiazide increased with increase in concentration of losartan potassium as 
observed from the phase solubility study. 
 
Mauro Cavinato et al., 23 in 2011 determined the effects of some important drug 
properties (such as particle size distribution, hygroscopicity and solubility) and 
process variables on the granule growth behaviour and final drug distribution in high 
shear wet granulation. Results have been analyzed in the light of widely accepted 
theories and some recently developed approaches. A mixture composed of drug, some 
excipients and a dry binder was processed using a lab-scale highshear mixer. Three 
common active pharmaceutical ingredients (paracetamol, caffeine and 
acetylsalicyliccid) were used within the initial formulation. Drug load was 50% (on 
weight basis). Influences of drug particle properties (e.g. particle size and shape, 
hygroscopicity) on the granule growth behaviour were evaluated. Particle size 
distribution (PSD) and granule morphology were monitored during the entire process 
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through sieve analysis and scanning electron microscope (SEM) image analysis. 
Resistance of the wet mass to mixing was furthermore measured using the impeller 
torque monitoring technique. 
 
NILS ROTTMANN et al., 24 in 2009 studied that Nowadays the buzzword “process 
optimization” has an unprecedented importance. This can be on one hand attributed to 
increasing cost pressure in pharmaceutical production and on the other hand, to an 
increasing environmental awareness in the industry. However, to address this concern, 
we have considered one of the most energy consuming processes in the industry – the 
film-coating process – with respect to the efficiency of several instant release film 
coating formulations, based on HPMC, PVA and a PEG-PVA graft co-polymer. By 
choosing an appropriate coating polymer or formulation, a process time reduction of 
more than 30 percent is achievable, a result that serves the purpose of both, cost 
reduction as well as environmental protection. 
 
SchreimerT et al., in 2005 25 investigated about the mechanism of immediate drug 
release from solid oral dosage forms. They found that starch and cellulose substances 
favoured the matrix disintegration and the generation of effective dissolution surface 
of the drug substances. They developed a mathematical model suitable for the 
characterization and optimization of immediate drug release by the choice and 
modification of excipients. 
Sameer Late Get al., 26in 2009 investigated the effects of disintegration promoting 
agent, lubricants, on optimized fast disintegrating tablets. Results of multiple linear 
regression analysis revealed that concentration of lubricant was found to be important 
for tablet dis- integration and hardness. 
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Van Kamp HVet al., in 2005 studied about the improvement of tabletting properties 
of super disintegrants by wet granulation. The crushing strength, disintegration and 
dissolution properties of tablets, made by et granulation with lactose as filler, gelatin 
as binder, potato starch as disintegrant and magnesium stearate as lubricant would be 
markedly improved when potato starch (20%) was replaced by much lower 
concentration(4%) of an insoluble super disintegrant, such as SSG or crospovidone. 
Magnus Alwuagwnet al., 27 in 2003 studied the disintegrant ability of Pleurotustuber-
regium in comparison with maize starch in preparation of paracetmol tablets via wet 
granulation method. The results indicated that P.tuber-regiumand maize starch have 
similar true, bulk and tapped density values. 
Makino Todashi et al., 28 in 2000 studied on the effects of binder distribution of 
granules and granule hardness on the compressibility of granules for tablets 
manufactured by wet granulation. This study suggested that uniform binder 
distribution of granules on wet granulation is important for the excellent 
compressibility of granules for tablets. 
Satia MC., et al in 1995 29 has reported on Losartan, an angiotenisis-II receptor 
antagomist, and a few of its congeners; A new therapeutic class in the management of 
hypertension. 
 
JakobKristensenet et al., in 30 2000 studied on comparison of granule and tablet 
properties prepared by wet granulation in a rotary processor and a conventional fluid 
bed. This study is indicated that rotary processor gave rise to more dense granules 
with better flow properties than fluid bed granules. 
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Maja Lusina et al., in 200531 studied the stability of losartan potassium and 
hydrochlorthiazide tablets The purpose of stability testing is to investigate how the 
quality of a drug product changes with time under the influence of environmental 
factors, to establish a shelf life for the product and to recommend storage conditions. 
Stability study of losartan/hydrochlorothiazide tablets is presented. Losartan 
(angiotensin II receptor antagonist) and hydrochlorothiazide (diuretic) are 
successfully used in association in the treatment of hypertension. Stability study of 
losartan/hydrochlorothiazide tablets consisted of three steps: stress test (forced 
degradation study), preliminary testing (selection of packaging) and formal stability 
testing. The results of stress test suggested that losartan/hydrochlorothiazide tablets 
are sensitive to moisture. It was demonstrated that the developed analytical methods 
are stability indicating. Additional preliminary testing was performed in order to 
select appropriate packaging for losartan/hydrochlorothiazide tablets. 
 
G.K. Aulakh et al., in 200732 studied about the non-peptide angiotensin receptor 
antagonists. The renin–angiotensin–aldosterone-system (RAAS) is an important 
regulator of blood pressure and fluid-electrolyte homeostasis. RAAS has been 
implicated in pathogenesis of hypertension, congestive heart failure, and chronic renal 
failure. Aliskiren is the first non-peptide orally active renin inhibitor approved by 
FDA. Angiotensin Converting Enzyme (ACE) Inhibitors are associated with frequent 
side effects such as cough and angio-oedema. Recently, the role of ACE2 and neutral 
endopeptidase (NEP) in the formation of an important active metabolite/mediator of 
RAAS, ang 1–7, has initiated attempts towards development of ACE2 inhibitors and 
combined ACE/NEP inhibitors. 
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Jennifer Wang et al., in 201033 studied the lubrication in tablets. Theoretical aspects 
and practical considerations of lubrication in tablet compression are reviewed in 
thispaper. Properties of the materials that are often used as lubricants, such as 
magnesium stearate, in tablet dosage form are summarized. The manufacturing 
process factors that may affect tablet lubrication are discussed. As important as the 
lubricants in tablet formulations are, their presence can cause some changes to the 
tablet physical and chemical properties. Furthermore, a detailed review is provided on 
the methodologies used to characterize lubrication process during tablet compression 
with relevant process analytical technologies. Finally, the Quality-by-Design 
considerations for tablet formulation and process development in terms of lubrication 
are discussed. 
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3. AIM AND OBJECTIVE 
 
 The main objective of this work is to formulate an conventional release oral solid 
dosage form of Losartan potassium and Hydrochlorthiazide which is considered to be stable, 
robust quality and pharmaceutically equivalent to that of the reference [marketed] product for the 
treatment of Hypertension. 
 
 The aim is to develop and evaluate immediate release tablets with different 
compositions of excipients which will meet the standards to that of the reference product with 
the subsequent achievement of invitro correlation with the reference product.  
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4. PLAN OF WORK 
 
1. Literature review 
 
2. Pre compression studies:- 
a. Bulk density 
b. Tapped density 
c. Compressibility index 
d. Angle of repose 
e. Hausner’s ratio 
 
3. Formulation of tablets by wet granulation  method 
 
4. Evaluation of Formulated tablets 
o Appearance 
o Hardness 
o Weight variation test 
o Friability 
o Thickness 
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o Disintegration 
o Dissolution 
o Drug content 
o Stability studies . 
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   4. MATERIALS AND METHODS 
 
Table: 1 Materials 
 
S.NO RAW MATERIALS MANUFACTURER 
1 Losartan potassium aurobindopharmaltd.,Hyderabad 
2 Hydrochlorthiazide aurobindopharmaltd.,Hyderabad 
3 Aerosil 200 pharma Signet Chemicals, Mumbai 
4 Lactose Monohydrate Colorcon, Mumbai 
5 Avicel 102 Signet Chemicals, Mumbai 
6 HPMC Aurolab, Madurai 
7 Starch 1500 Signet Chemicals, Mumbai 
8 Avicel 101 Signet Chemicals, Mumbai 
9 
Low substituted hydroxyl propyl 
cellulose 
Colorcon Verna Industrial estate area, Goa 
 
10 Magnesium stearate SD Fine Chemicals limited, Mumbai 
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Table:2 List of Equipments 
 
S. 
No. 
EQUIPMENT MANUFACTURER Model NO 
1 
Electronic Balance Shimadzu AUX220 
2 Sieves United Engineering 
Ltd. 
ASL00 
3 
Tap density Tester Electrolab ETD-020 
4 
Laboratory Stirrer Remi RQT-124A 
5 
Rapid dryer Retsch TG-200 
6 Dissolution test apparatus Electro lab USP XXII TDT-08L 
7 
Disintegration Tester Electrolab ED-2L 
8 Hardness tester Pharmatest PTB-311E 
9 
Friabilator Electrolab EF-1W 
10 Tablet Compression machine-
16Station 
Cadmch Machinery co. 
Pvt.Ltd CM D3-16 
11 
Thickness tester(vernier calipers) Pharmatest ET-1P 
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4.1 DRUG PROFILE  
 
LOSARTAN POTASSIUM : 
 Losartan potassium42,43 is an angiotensin II receptor (type AT1) antagonist. 
Losartan is an orally active agent that undergoes substantial first-pass metabolism by 
cytochrome P450 enzymes. It is converted into a carboxylic acid metabolite. Losartan 
metabolites have been identified in human plasma and urine. In addition to the 
carboxylic acid metabolite, several metabolites are formed.                                         . 
 
Structure :  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 Molecular Formula :      C22H22ClKN6O 
 
Molecular Weight    :       461.0 
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Chemical name   : 
2-butyl-4-chloro-1-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]imidazole-5-methanol 
monopotassium salt. 
 
Limits  :  
 Losartan potassium contains not less than 98.5 % and not more than 
equivalent of 101.0 % of calculated with reference to the anhydrous substance. 
 
Properties  : 
 APPEARANCE  :     white to off-white free-flowing crystalline powder.  
 
Solubility  :  
It is freely soluble in water, soluble in alcohols, and slightly soluble In 
common organic solvents, such as acetonitrile and methyl ethyl ketone. 
 
Mechanism of action: 
 Angiotensin II [formed from angiotensin I in a reaction catalyzed by 
angiotensin converting enzyme (ACE, kininase II)], is a potent vasoconstrictor, the 
primary vasoactive hormone of the renin-angiotensin system and an important 
component in the pathophysiology of hypertension. It also stimulates aldosterone 
secretion by the adrenal cortex. Losartan block the vasoconstrictor and aldosterone-
secreting effects of angiotensin II by selectively blocking the binding of angiotensin II 
to the AT1receptor found in many tissues, (e.g., vascularsmooth muscle, adrenal 
gland). There is also an AT2 receptor found in many tissues but it is not known to be 
associated with cardiovascular homeostasis. Both Losartan and its principal active 
metabolite do not exhibit any partial agonist activity at the AT1 receptor and have 
much greater affinity (about 1000-fold) for the AT1 receptor than for the AT2 
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receptor. In vitro binding studies indicate that Losartan is a reversible, competitive 
inhibitor of the AT1 receptor.   
 
Pharmacokinetics:  
  Losartan is readily absorbed from the gastrointestinal tract following 
oral administration. It undergoes frost pass metabolism to form a carboxylic acid 
metabolite E-3174 (EXP-3174). The terminal elimination half lives of Losartan and is 
about 1.5 to 2.5 hours. Losartan's bioavailability is about 32%. Following oral 
administration, 6 % of Losartan is excreted unchanged in the urine. After oral 
administration peak plasma levels are attained at 1hr for losartan and 3-4hrs for 
E3174. Both compounds are 98% plasma protein bound. The plasma t1/2 of losartan 
is 2hr, but that of E3174 is 6-9hr.  
 
Dose :  
Dosing must be individualized. The usual starting dose of Losartan potassium 
is 50 mg once daily, with 25 mg used in patients with possible depletion of 
intravascular volume (e.g., patients treated with diuretics) and patients with a history 
of hepatic impairment Losartan potassium can be administered once or twice daily 
with total daily doses ranging from 25 mg to 100 mg. 
 
Storage: 
Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F). Keep 
container tightly closed. Protect from light. 
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Adverse Reactions: 
 Adverse effects of Losartan have been reported to be usually mild and 
transient, and include dizziness and dose-related orthostatic hypotension. Hypotension 
may occur particularly patients with volume depletion (for example those who have 
high dose diuretics).  Hyperkalaemina has been reported. It appears less lightly then 
angiotesin-converting enzyme (ACE) inhibitors to cause cough.  
 
Uses and Administration: 
 Losartan is an angiotensin II receptor antagonist with antihypertensive activity 
due mainly to selectively blockade of AT1 receptors and the consequent reduced 
pressor effect of angiotensin II. It is given by mouth as the potassium salt in the 
management of hypertension. It has also been tried in heart failure.  
 
  In hypertension dose is 50 mg once daily. The maximum effect is 
achieved in about 3-6 weeks after initiating treatment. The dose may increased, if 
necessary, to 100 mg once daily. An initial dose of 25 mg once daily is suggested for 
the elderly over 75 years-of-age, and for patients with moderate to severe renal 
impairment (creatinine clearance less than 20 ml per minute ), or intravascular fluid 
depletion. A reduced dose should also be considered for patients with hepatic 
impairment.   
Availability: Trade names of Losartan potassium 
COZAAR 50 mg, 
COZAAR 100 mg  
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HYDROCHLORTHIAZIDE : 
  Structure : 
 
 
Molecular Formula   : C7H8ClN3O4S2 
 
Molecular Weight    :  297.74 
 
Chemical name   : 
2H-1,2,4-Benzothiadiazine-7-sulfonamide,6-chloro-3,4-dihydro-,1,1-dioxide.  
6-Chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide [58-93-
5]. 
 
Solubility:  Very slightly soluble in water, soluble in aqueous solutions of 
Inorganic bases, e.g. sodium hydroxide / ammonium hydroxide, 
and in organic bases like n-butylamine 
 
Limits  :  
Hydrochlorothiazide contains not less than 98.0percent and not more than 
102.0percent of C7H8ClN3O4S2,calculated on the dried basis. 
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Uses : 
This medication is used to treat high blood pressure. Lowering high blood pressure 
helps prevent strokes, heart attacks, and kidney problems. Hydrochlorothiazide is a 
"water pill" (diuretic) that causes you to make more urine. This helps your body get 
rid of extra salt and water. This medication also reduces extra fluid in the body 
(edema) caused by conditions such as heart failure, liver disease, or kidney disease. 
This can lessen symptoms such as shortness of breath or swelling in your ankles or 
feet. 
 
Mechanism of action : 
Hydrochlorothiazide belongs to the thiazide class of diuretics. It reduces blood 
volume by acting on the kidneys to reduce sodium (Na) reabsorption in the distal 
convoluted tubule. The major site of action in the nephron appears on an 
electroneutral Na+-Cl- co-transporter by competing for the chloride site on the 
transporter. By impairing Na transport in the distal convoluted tubule, 
hydrochlorothiazide induces a natriuresis and concomitant water loss. Thiazides 
increase the reabsorption of calcium in this segment in a manner unrelated to sodium 
transport.[6] Additionally, by other mechanisms, HCTZ is believed to lower peripheral 
vascular resistance. 
 
Pharmacokinetics: 
The bioavailability of hydrochlorothiazide from 50-mg oral tablet doses was 
examined in healthy male volunteers under fasting and nonfasting conditions. 
Bioavailability was examined from plasma levels and urinary excretion of unchanged 
drug. The pharmacokinetics of hydrochlorothiazide in plasma could be described in 
terms of a triexponential function, and the mean drug half-lives determined from the 
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three exponents were 1.0, 2.2, and 9.0 hr. Changing the accompanying fluid volume 
had no significant effect on hydrochlorothiazide absorption in fasted subjects. Plasma 
drug levels were significantly reduced in nonfasted individuals, compared with those 
in fasted individuals. A similar trend was observed in the urinary excretion of 
hydrochlorothiazide, but differences between treatments were not significant (p > 
0.05). Mean 48-hr urinary recovery of hydrochlorothiazide was 70.5% of the dose in 
nonfasted subjects, and 73.5 and 75.0% of the dose in fasted subjects receiving the 
drug with 20 and 250 ml of water, respectively. 
 
Dosage: 
For high blood pressure control with HCTZ, dosage recommendations typically start 
at 25 mg once a day. Depending on your response to the medication, your healthcare 
provider may adjust your dosage accordingly. The suggested dosage for treating water 
retention varies between 25 mg and 100 mg, taken in a single dose or divided and 
taken more frequently. Generally, the recommended HCTZ dosage for infants and 
children is 0.5 mg to 1 mg per pound of body weight each day. 
Storage: 
Store in a well closed container, at room temperature. Protect from Moisture and 
Heat.  
Store Below 40°C. Protect from Sunlight and Heat. 
Stability: 
Finished product stability studies have been conducted in accordance with 
currentguidelines and results were within the proposed specification limits. Based on 
theresults, a shelf-life of 36 months has been set, which is satisfactory. 
Storageconditions are “Do not store above 30°C”, “Store in the original packaging”. 
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4.2 EXCIPIENTS PROFILE 
 
MICRO CRYSTALLINE CELLULOSE43 
Synonyms:   Avicel PH, Celex, cellulose gel, celphere. 
Empirical formula and molecular weight: (C6H10O5)n   =  36000W 
Where, n = 220. 
Structure: 
 
 
Functional category: Adsorbent, suspending agent, tablet and capsule diluent, 
tabletdisintegrant. 
Description:  Microcrystalline cellulose is purified, partially depolymerized cellulose 
that occurs as a white, odorless, tasteless, crystalline powder composed 
of porous particles.  
 
pH  : 5.0 -7.5 
 
Melting point: 260 - 2700C 
 
Stability: It is stable though hygroscopic material. 
 
Storage: Should be stored in well closed container in a cool, dry place.  
 
Safety : Non- toxic and non-irritant material. Consumption of large quantities of 
cellulose may         have a laxative effect 
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Handling precautions: Itmay be irritant to eyes Gloves, eye protection and a dust 
mask is recommended 
 
Applications in pharmaceutical formulation or technology:  
• Microcrystalline cellulose is widely used in pharmaceuticals, primarily as a 
binder/diluent in oral tablet and capsule formulations where it is used in both 
wet-granulation and direct-compression processes.  
• In addition to its use as binder/diluents, microcrystalline cellulose also has 
some lubricant and disintegrant properties that make it useful in tableting. 
Microcrystalline cellulose is also used in cosmetics and food products. 
 
MAGNESIUM STEARATE44 
Synonyms:Magnesium octadecanoate; octadecanoic acid, magnesium salt; stearic 
acid. 
Chemical Name: Octadecanoic acid magnesium salt. 
Empirical Formula:C36H70MgO4 
Description : Magnesium stearate is a very fine, light white, precipitated or milled, 
impalpable powder of low bulk density, having a faint odor of stearic 
acid and a characteristic taste. The powder is greasy to touch and 
readily adheres to the skin. 
Molecular Weight: 591.34 
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Functional category: Tablet and capsule lubricant. 
Stability and Storage Conditions: It is stable and should be stored in a well 
closedcontainer in a cool, dry place 
Safety : Magnesium stearate is widely used as a pharmaceutical excipient and is 
generally regarded as being nontoxic following oral administration. However, oral 
consumption of large quantities may produce a laxative effect or mucosal irritation. 
Applications in Pharmaceutical Formulation or Technology: 
Magnesium stearate is widely used in cosmetics, foods, and pharmaceutical 
formulations. It is primarily used as an lubricant in capsule and tablet manufacture at 
concentrations between 0.25% and 5.0% w/w. It is also used in barrier creams.  
 
 LACTOSE 
Synonyms:Pharmatose,milk sugar,prismalac. 
 
Structure: 
 
 
Molecular weight:360.31 
 
Functional category:Tablet and capsule diluent, diluents for dry power inhalers. 
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Description: Lactose occurs white to off crystalline particles or powder. It is odorless 
aslightly sweet tasting. 
Stability and storage conditions: 
Mold growth occurs under humid conditions (80% relative humidity and 
above). It may develop a brown coloration on storage. It should be stored in a well 
closed container in a cool, dry place 
 
Applications: 
Lactose is widely used as filler or diluents in capsules and tablets and to a 
more limited extent in lyophilized products and infant feed formulas. Usually fine 
grades of lactose are used in the preparation of tablets by the wet granulation method 
or when milling during processing is carried out, since the fine size permits better 
mixing with other formulation ingredient and utilizes the binder more efficiently. 
 
STARCH : 
Nonproprietary Names 
• BP:   Maize starch 
•     Potato starch 
•     Rice starch 
•    Tapioca starch 
•     Wheat starch 
• JP:    Corn starch 
•     Potato starch 
•     Rice starch 
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•     Wheat starch 
• PhEur:    Maydis amylum (maize starch) 
•     Solani amylum (potato starch) 
•     Oryzae amylum (rice starch) 
•     Tritici amylum (wheat starch) 
• USPNF:    Corn starch 
•     Potato starch 
•     Tapioca 
•     Wheat starch 
• Note that the USPNF 23 has individual monographs for corn (Zea mays), 
potato (Solanum tuberosum), tapioca (Manihot utilissima Pohl) and wheat 
starch (Triticum aestivum). The PhEur 2005 has monographs for each of these 
starches, except tapioca starch, along with an additional monograph for rice 
starch, Oryza sativa. Also note that the PhEur 2005 Suppl 5.0 contains an 
updated monograph for maize (corn) starch. The BP 2004 similarly describes 
maize, potato, rice, tapioca ( cassava), and wheat starch in individual 
monographs, tapioca starch being obtained from the rhizomes of Manihot 
utilissima Pohl. The JP 2001  
• similarly describes corn (maize), rice, potato and wheat starch in separate 
monographs. 
Synonyms 
Amido; amidon; amilo; amylum; Aytex P; C*PharmGel; Fluftex W; Instant Pure-
Cote; Melojel; Meritena; Paygel 55; Perfectamyl D6PH; Pure-Bind; Pure-Cote; Pure-
Dent; Pure-Gel; Pure-Set; Purity 21; Purity 826; Tablet White. 
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Chemical Name and CAS Registry Number 
Starch [9005-25-8] 
Empirical Formula and Molecular Weight 
(C6H10O5)n 50 000–160 000 
where n = 300–1000. 
Starch consists of amylose and amylopectin, two polysaccharides based on α-glucose.  
Structural Formula 
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Functional Category 
Glidant; tablet and capsule diluent; tablet and capsule disintegrant; tablet binder. 
Applications in Pharmaceutical Formulation or Technology 
Starch is used as an excipient primarily in oral solid-dosage formulations where it is 
utilized as a binder, diluent, and disintegrant. 
As a diluent, starch is used for the preparation of standardized triturates of colorants 
or potent drugs to facilitate subsequent mixing or blending processes in 
manufacturing operations. Starch is also used in dry-filled capsule formulations for 
volume adjustment of the fill matrix. 
In tablet formulations, freshly prepared starch paste is used at a concentration of 5–
25% w/w in tablet granulations as a binder. Selection of the quantity required in a 
given system is determined by optimization studies, using parameters such as granule 
friability, tablet friability, hardness, disintegration rate, and drug dissolution rate. 
Starch is one of the most commonly used tablet disintegrants at concentrations of 3–
15% w/w. However, unmodified starch does not compress well and tends to increase 
tablet friability and capping if used in high concentrations. In granulated formulations, 
about half the total starch content is included in the granulation mixture and the 
balance as part of the final blend with the dried granulation. Also, when used as a 
disintegrant, starch exhibits type II isotherms and has a high specific surface for water 
sorption. 
Starch has been investigated as an excipient in novel drug delivery systems for 
nasal,oral, periodontal,  and other site-specific delivery systems. 
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Starch is also used in topical preparations; for example, it is widely used in dusting 
powders for its absorbency, and is used as a protective covering in ointment 
formulations applied to the skin. Starch mucilage has also been applied to the skin as 
an emollient, has formed the base of some enemas, and has been used in the treatment 
of iodine poisoning. 
 
COLLIDAL SILICONE DIOXIDE 
 
Synonyms : Aerosil; Cab-O-Sil; Cab-O-Sil M-5P; colloidal silica;                  
fumedsilica; 
 
Description : Colloidal silicon dioxide is a submicroscopic fumed silica with 
aparticle size of about 15 nm. It is a light, loose, bluish-white-colored,odorless, 
tasteless, amorphous powder. 
 
Functional categories : Adsorbent; anticaking agent; emulsion stabilizer; glidant; 
suspending agent; tablet disintegrant; thermal stabilizer; viscosity-increasingagent. 
 
Solubility : Practically insoluble in organic solvents, water, and acids, except 
hydrofluoric acid; soluble in hot solutions of alkali hydroxide. Forms a colloidal 
dispersion with water. For Aerosil,solubility in water is 150 mg/L at 258C (pH 7). 
 
pH : 3.5-5.5 for a 4%w/w  aqueous  solution 
 
Bulk Density : 0.029–0.042 g/cm3 
 
Melting Point  : 1600 0C 
 
Stability and storage conditions : Colloidal silicon dioxide is hygroscopic but 
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adsorbs large quantitiesof water without liquefyingat a pH greater than 7.5 the 
viscosityincreasing properties of colloidal silicon dioxide are reduced. 
 
Incompatibility : Incompatible with diethylstilbestrol preparations 
Applications  : Colloidal silicon dioxide is also used to stabilize emulsions 
andas a thixotropic thickening and suspending agent in gels and semisolid 
preparations.(5Colloidal silicon dioxide is also used as an adsorbent during 
thepreparation of wax microspheres; as a thickening agent for topical preparations; 
and has been used to aid the freeze-drying of nanocapsules and nanosphere 
suspensions. 
 
HYPROMELLOSE (HPMC K4M) 
 Hypromellose45 is a white or slightly off-white, fibrous or granular powder. 
Swells in water and produces a clear to opalescent, viscous, colloidal mixture. 
Insoluble in dehydrated alcohol, ether and in chloroform. 
 
 NF Category : 
Coating agent, suspending and/or viscosity increasing agent, tablet binder. 
Hypromellose is propylene glycol ether of methylcellulose. When dried to 
1050C for 2 hours, it contains methoxy (-OCH3) and hydroxypropoxy (-
OCH2CHOHCH3) groups conforming to the limits for the types of Hypromellose 
(hydroxypropylmethylcellulose). 
 
Substitution type Methoxy (percent) Hydroxypropoxy(percent) 
          2208 Minimum 
Maximum 
Minimum 
Maximum 
19.0 24.0 4.0 12.0 
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Storage:  
Hypromellose should be stored in a well closed container, in a cool, dry place. 
 
Pharmaceutical Applications:  
• Hypromellose is widely used in oral, ophthalmic and topical 
pharmaceutical formulations. 
• Low viscosity grades of HPMC are used in aqueous film coating in 
tablet formulations. 
• High viscosity grades are used in solvent film coating. 
• 2.5 % high viscosity grades are used to retard the release of water 
soluble drugs as binder in tablet granules.  
• As thickening agent added to vehicles of eye drops and artificial fear 
solutions at 0.45-1.0 % concentrations.  
• It is also used as productive colloid to prevent droplets and particles 
from coalescing or agglomerating.  
• It is used as emulsifier, suspending agent, stabilizer in gels and in 
ointments. 
• It is also used as an additive in plastic bandages. 
• It is also widely used in cosmetics and food products. 
 
Typical Viscosity:  
Methocel product 
  
USP 28 designation 
 
Nominal viscosity (mPa s) 
Methocel K4M 2208  4000 
Methocel K15M 2208 15000 
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Table-3    Formulae 
 
Sl.No. Chemicals F1 F2 F3 F4 F5 F6 F7 
1 Losartan 
potassium 
100 100 100 100 100 100 100 
2 HCTZ 12.5 12.5 12.5 12.5 12.5 12.5 12.5 
3 Avicel 101 70 70 60 50 40 30 30 
4 L- HPC - - - - 12.5 15.0 15.0 
5 Avicel 200 - - - 10 20 30 30 
6 Starch 1500 10.0 12.5 15.0 20.0 25.0 25.0 30.0 
7 HPMC 10 10 10 12.5 - - - 
8 Aerosil 200 
Pharma 
90 90 90 - - - - 
9 Pharmatose 
DCL 11 
- - - 80 80 80 80 
10 Magnesium 
Stearate 
1.8 1.8 1.8 1.8 1.8 1.8 1.8 
Granulating fluid 
11 Purified water q.s q.s q.s q.s q.s q.s q.s 
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4.3 MANUFACTURING: 
 
4.3.1 Manufacture of the Tableting Blend38: 
 In the tablet pressing process, the main guideline is to ensure that the 
appropriate amount of active ingredient is in each tablet. Hence, all the ingredients 
should be well-mixed. If a sufficiently homogenous mixture of the components cannot 
be obtained with simple blending processes, the ingredients must be granulated prior 
to compression to assure an even distribution of the active compound in the final 
tablet. Two basic techniques are used to granulate powders for compression into a 
tablet: wet granulation and dry granulation. Powders that can be mixed well do not 
require granulation and can be compressed into tablets through direct compression. 
 
4.4 Preparation of LOSARTAN/HCTZ tablets by wet granulation method 39 :  
 
4.4.1 Sifting: 
Microcrystaline Cellulose (Avicel PH 101) and Lactose Monohydrate (Pharmatose 
200M) sifted separately through # 40 mesh(ASTM,425 µm) in both batches. In 1 st 
batch losartan potassium sifted through #40 mesh and in 2nd batch through #30 mesh 
to improve the sifting process. 
 
4.4.2 Dry Mixing: 
Sifted materials were loaded into Rapid Mixer Granulator and dry mixing was carried 
out for  5+5+5 minutes in 1st batch and in 2nd batch for 10 min with Impeller at slow 
speed.Unit dose samples were collected and submitted for analysis.The results found 
to be satisfactory within the acceptable limits. 
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4.4.3 Granulation: 
Granulation fluid(Purified water-fluid uptake-10%) was added over a period of 5-6 
min with impeller at slow speed in 1st batch and in 2nd batch the fluid was added in 
3min10sec.Kneading was done for 2 min in 1st batch and in 2nd batch to have better 
granules Kneading was done for 30 sec with impeller at slo9w speed in both batches. 
 
4.4.4 Drying: 
Drying was carried out in Fluidized Bed Drier at an inlet temperature of 55±5°c in 1st 
batch and in 2nd batch drying was carried out with an inlet temperature of 60±5°c to 
have a better control of drying.Loss on Drying of the granules at the end of drying 
was found to be 3.98%w/w(lot I) and 3.81%w/w(Lot II) in 1st batch and in 2nd batch 
3.85%w/w against limit of 3.0-5.0%w/w. 
 
4.4.5 Sifting & Milling: 
Dried granules were sifted through #30 mesh(ASTM,600µm) & retentions milled 
through 1.0mm screen at medium speed,knives forward configuration.Milled granules 
were sifted through #30 mesh(ASTM<600µm).The retentions were milled through 
1.0mm screen at fast speed,knives forward.Ensured all the material passed through 30 
mesh(ASTM<600µm) in both batches. 
 
4.4.6 Extra granular Materials Sifting: 
Microcrystalline Cellulose(Avicel PH 200)sifted through #30 sieve(ASTM 600µm), 
Pregelatinized Starch(stach 1500) & Low Substituted  HYDROXYPROPYL 
Cellulose(L-HPC(LH-11)) sifted through #40 sieve(ASTM 425µm) Magnesium 
stearate was sifted through #60 mesh(ASTM,25.0µm) in both batches. 
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4.4.7 Prelubrication: 
Sifted Extra granular material was added into Octagonal Blender and mixed for 
5+5+5 min in  1st batch and in 2nd batch for 10 min in which unit dose samples were 
collected and submitted for analysis. The results found to be satisfactory within the 
acceptable limits. 
 
4.4.8 Lubrication: 
Sifted magnesium state was added into Octoganal blender and mixed for 3 min in 
both batches.Unit dose samples were collected and submitted for analysis. The results 
found to be satisfactory within the acceptable limits. 
In process blend analysis is complying with the proposed specifications. 
 
4.4.9 Compression: 
Compression was done on 16-station compression machine.All physical parameters 
were found consistent. 
 
 
4.4.10  WET GRANULATION PROCESS40: 
 wet granulation forms the granules by binding the powders  together with an 
adhesive, instead of by compaction. In this process the excipients are weighed and are 
sifted through 30#and the these ingredients are loaded in the rapid mixer granulator 
and are mixed for about two minutes with impeller at slow speed. Then the both the 
drug are mixed along with all the excipients which are mixed previously at the speeds 
of  the impeller slow for about six minutes and there after the ingredients with drugs is 
mixed in the rapid mixer granulator at impeller and chopper fast for about two 
minutes these two minutes the impeller and chopper are in fast speed as they have to 
mix all the ingredients along with the granulating fluid which is purified water the 
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impeller is used to mix the granules properly and the chopper is used to break the 
agglomerates properly and then the final blend is checked whether the granules are 
formed. Then after the granules are formed they are to be dried that the LOD should 
be less than 3% the granules are dried for about 15 minutes with an inlet temperature 
of  50+/- 50 C. then the granules are milled to break the agglomerates present in the 
final blend or granules. The screen size of the mill is 40 and after breaking all the 
agglomerates i.e., after collecting all the material the granules are blended in an 
octagonal blender for 10 minutes by adding the magnesium stearate. 
 
   The total weight of granules formed is 150gm from which the 
500 tablets are punched using caddmach 16 stn punching machine with 8.5 mm 
circular punches, which is used in the further process like coating. The process of 
coating is done with opadry white as coating material used for film coating. The 
coating process is done in NEOCOTA. For the optimized batch coating is done by 
using coating solution (50 mg with 200 ml of purified water). 
 
4.4.11 Coating 41: 
In the first batch, during coating gun jamming, rough surface and shade variation was 
observed. As recommended by the formulation research from second batch onwards 
%w/w solids was decreased from 12%w/w to 10%w/w and coating efficiency was 
decreased from 90% to 80%. Coated tablets are complying with the drug product 
release specifications. 
 
Coating procedure:  
 
Pan Speed (RPM) 10-14 
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Air Pressure (kg/cm2 2-2.5 
Blower Air Volume (CFM) 30 
Solid Content (%) 12-15 
Baffels 4 
Tablet Weight 150gm 
Bed Temperature (°C) 35-40 
Spray Nozzle (mm) 1 
No. of Spray Gun 1 
Inlet Air temperature(°C ) 70 
 
 
4.5 Drug-excipient compatibility studies42: 
                      The proper design and the formulation of a dosage form require 
consideration of the physical, chemical and biological characteristics of the drug and 
excipients used in fabricating the product. The drug and excipients must be 
compatible with one another to produce a product i.e. stable, efficacious, attractive, 
easy to administer and safe. 
 
                      The compatibility studies provide the frame work for the drugs 
combination with the excipients in the fabrication of the dosage form. The study was 
carried out to establish that the therapeutically active drug has not undergone any 
changes, after it has been subjected to processing steps during formulation of tablets. 
 
                      Compatibility studies are carried out by mixing definite properties of 
drug and excipient and kept in glass vials, which is stored at 55°C for one month. 
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4.6 Preformulaton Studies33 
 
 4.6.1 Bulk Density34: 
 It refers to a measurement to describe packing of particles. Bulk 
density is used to determine the amount of drug that occupies the volume in 
mg/ml 
Where, 
         m   = mass of the blend 
 vi= untapped volume 
 
Procedure: 
Weighed quantity of API was transferred into 100 ml measuring 
cylinder without tapping during transfer. The volume occupied by DRUG was 
measured. Bulk density was measured by using formula 
 
Pi=m/vi 
 
4.6.2 Tapped Density34:  
            Procedure:  
Weighed quantity of API was taken into a graduated cylinder. Volume occupied by 
DRUG was noted down. Then the cylinder was subjected to 500, 750 & 1250 taps in 
tap density tester (Electro Lab USP II). According to USP, the blend was subjected 
for 500 taps. % Volume variation was calculated and subjected for additional 750 
taps. % Variation is calculated.   
 
Pi   = m/vi 
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4.6.3 Compressibility Index35:  
Weighed API was transferred to 100ml-graduated cylinder and 
subjected to 500,750&1250 taps in tap density tester (Electro lab). The 
difference between two taps should be less than 2%. The %of compressibility 
index calculated using formula 
 
 
  
Limits : 
S.No Compressibility index Flow 
1 5-12 Free flow 
2 12-16 Good flow 
3 18-21 Fair 
4 23-25 Poor 
5 33-38 Verypoor 
6 >40 Extremelypoor 
 
4.6.4 Hausner’s Ratio36:  
It is measurement of frictional resistance of the drug. The ideal range should 
be 1.2 –1.5.it is the determined by the ratio of tapped density and bulk density. 
 
Hausner’s ratio = vi/ vt 
 
Pt= m/vt 
CI = vi –vt/ vi x 100 
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Where    vt=Tapped volume 
                                   vi  = untapped volume 
       Limits:  
S.No Hausner’ ratio Flow 
1 1-1.2 Free flowing 
2 1.2-1.6 Cohesive powder 
 
 
 
4.6.5 Angle of Repose37: -    
The angle of repose has been used to characterize the flow properties of solids. Angle 
of repose is a characteristic related to interparticulate friction or resistance to 
movement between particles. This is the maximum angle possible between surface of 
pile of powder or granules and the horizontal plane.  
                                      Tan θ = h / r 
θ = Tan –1 h / r 
      Where, θ = angle of repose, h = height, r = radius. 
A funnel was fixed at a height approximately of 2-4 cm over the platform. The 
loose powder was slowly passed along the wall of funnel, till the cone of the powder 
formed .Determine the angle of repose by measuring the height of the cone of powder 
and radius of the heap of powder. 
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 Flow Properties and Corresponding Angles of Repose 
Flow Property Angle of Repose (degrees) 
Excellent 25–30 
Good 31–35 
Fair - aid not needed 36–40 
Passable - may hang up 41–45 
Poor - must agitate, vibrate 46–55 
Very poor 56–65 
Very, very poor >66 
 
4.6.6 Particle size distribution: The size was determined by using eye piece 
micrometer. The eye piece micrometer was calibrated using stage micrometer. A 
smear of drug was prepared on a glass slide and utilizing eye piece micrometer the 
particle size was determined. 
 
4.6.7 Solubility:  Freely soluble in water. 
                                             Soluble in alcohol and 
                                            Slightly soluble in acetonitrile and methyl ethyl ketone 
 
4.7 EVALUATION OF TABLETS43: 
            To design tablets and later monitor tablet production quality, quantitative 
evaluation and assessment of tablet chemical, physical and bioavailability properties 
must be made. 
           The important parameters in the evaluation of tablets can be divided into 
physical and chemical parameters. 
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4.7.1 Physical appearance: 
 The general appearance of tablets, its visual identity and overall elegance is 
essential for consumer acceptance. The control of general appearance of tablet 
involves measurement of number of attributes such as tablet size, shape, color, 
presence or absence of odor, taste, surface texture and consistency of any 
identification marks.  
 
4.7.2 Hardness test: 
 This is the force required to break a tablet in a diametric compression. 
Hardness of the tablet is determined by Stock’s Monsanto hardness tester which 
consists of a barrel with a compressible spring. The pointer moves along the gauze in 
the barrel fracture. The tablet hardness of 5 kg is considered as suitable for handing 
the tablet. (Values are given in Table No:14) 
 
4.7.3 Tablet size and Thickness: 
      Control of physical dimensions of the tablets such as size and thickness is 
essential for consumer acceptance and tablet-tablet uniformity. The diameter size and 
punch size of tablets depends on the die and punches selected for making the tablets. 
The thickness of tablet is measured by Vernier Calipers scale. The thickness of the 
tablet related to the tablet hardness and can be used an initial control parameter. 
Tablet thickness should be controlled within a ±5%. In addition thickness must be 
controlled to facilitate packaging.(Values are given in Table No:15) 
 
4.7.4 Friability: 
 This test is performed to evaluate the ability of tablets to withstand abrasion 
in packing, handling and transporting. Initial weight of 20 tablets is taken and these 
are placed in the friabilator, rotating at 25rpm for 4min. The difference in the weight 
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is noted and expressed as percentage. It should be preferably between 0.5 to 1.0%. 
(Values are given in Table No: 16) 
 
4.7.5 Average weight of Tablets: 
It is desirable that all the tablets of a particular batch should be uniform in 
weight. If any weight variation is there, that should fall within the prescribed limits: 
±10% for tablets weighing 300mg or less 
±7.5% for tablets weighing 300mg to 315mg 
                           ±5% for tablets weighing more than 315mg 
 
 Twenty tablets were taken randomly and weighed accurately. The average 
weight is calculated by -  
                      Average weight = weight of 20 tablets 
                            20 
 
4.7.6 Disintegration test: 
 For most tablets the first important step toward solution is break down of 
tablet into smaller particles or granules, a process known as disintegration. This is one 
of the important quality control tests for disintegrating type tablets. Six tablets are 
tested for disintegration time using USP XXII apparatus. Disintegration type 
conventional release tablets are tested for disintegrating time. (Values are given in 
Table No:18 ) 
 
4.7.7 Construction of Calibration curve of Losartan Potassium 
Accurately weighed 100 mg of Losartan potassium and transferred into 100 ml of 
volumetric flask and dissolved in small quantity of methanol and diluted with 6.8 
phosphate buffer up to the mark to give stock solution 1 mg/ml. 1 ml was taken from 
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stock solution in another volumetric flask and diluted up to 100 ml to give a stock 
solution 10 µg/ml. Further dilutions were made from 2-40 µg/ml with 6.8 phosphate 
buffer and absorbance was measured at 235 nm. 
 
 
Table-4 : Calibration curve of Losartan potassium in pH 6.8 phosphate buffer at       
             235 nm 
 
 
 
 
S.No.              Concentration    Absorbance 
1             2 µg/ml 0.122 
2             4 µg/ml 0.227 
3             6 µg/ml 0.343 
4             8 µg/ml 0.450 
5             10 µg/ml 0.562 
6             12 µg/ml 0.670 
7             14 µg/ml 0.779 
8             16 µg/ml 0.887 
9             18 µg/ml 0.981 
10             20 µg/ml 1.074 
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Fig. No:5  Calibration curve of Losartan potassium 
 
4.7.7 INVITRO DISSOLUTION STUDIES OF TABLETS45:  
                   Dissolution studies were carried out for all the formulations combinations 
in triplicate, employing USP XXVII paddle method and 900ml of pH 6.8 phosphate 
buffer as the dissolution medium. The medium was allowed to equilibrate to temp of  
37°c + 0.5°c. Tablet was placed in the vessel and the vessel was covered the apparatus 
was operated for 1 hr in pH 6.8 phosphate buffer at 50 rpm. At definite time intervals 
of 5 ml of the aliquot of sample was with drawn periodically and the volume replaced 
with equivalent amount of the fresh dissolution medium. The samples were analyzed 
spectrophotometrically at 235 nm using uv-spectrophotometer.  
 
4.7.7.1 Dissolution parameters:  
Apparatus  -- USP-II,  
Dissolution Medium  -- pH 6.8 phosphate buffer 
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RPM    -- 50 
Sampling intervals  -- 5, 10, 15, 20, 30 and 45. 
Temperature  -- 37°c + 0.5°c 
 
4.7.8 Release Kinetics 46  
 The analysis of drug release mechanism from a pharmaceutical dosage from is 
an important but complicated process and is practically evident in the case of matrix 
systems. As a model-dependent approach, the dissolution data was fitted to five 
popular release models such as zero-order, first-order, diffusion and exponential 
equations, which have been described in the literature. The order of drug release from 
matrix systems was described by using zero order kinetics or first orders kinetics. The 
mechanism of drug release from matrix systems was studied by using Higuchi 
equation, erosion equation and Peppas-Korsemeyer equation. The results are given in 
Table 26. 
 
4.7.8.1 Zero Order Release Kinetics: 
  It defines a linear relationship between the fraction of drug released 
versus time. 
Q = kot 
 
 Where, Q is the fraction of drug released at time t and kois the zero order 
release rate constant. 
 A plot of the fraction of drug released against time will be linear if the release 
obeys zero order release kinetics. 
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4.7.8.2 First Order Release Kinetics: 
 Wagner assuming that the exposed surface area of a tablet decreased 
exponentially with time during dissolution process suggested that drug release from 
most of the slow release tablets could be described adequately by apparent first-order 
kinetics. The equation that describes first order kinetics is 
In (1-Q) = - K1t 
Where, Q is the fraction of drug released at time t and k1 is the first order release rate 
constant. 
 Thus, a plot of the logarithm of the fraction of drug remained against time will 
be linear if the release obeys first order release kinetics. 
 
4.7.8.3 Higuchi’s equation: 
  It defines a linear dependence of the active fraction released per unit of 
surface (Q) on the square root of time. 
        Q=K2t½ 
 
Where, K2 is the release rate constant. 
A plot of the fraction of drug released against square root of time will be linear if the 
release obeys Higuchi equation. This equation describes drug release as a diffusion 
process based on the Fick’s law, square root time dependant. 
 
4.7.8.4 Power Law: 
 In order to define a model, which would represent a better fit for the 
formulation, dissolution data was further analyzed by Peppas and Korsemeyer 
equation (Power Law). 
Mt/Mα = K.tn  
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Where, Mt is the amount of drug released at time t and Mα is the amount released at 
time α, thus the Mt/Mαis the fraction of drug released at time t,k is the kinetic 
constant and n is the diffusional exponent. To characterize the mechanism for both 
solvent penetration and drug release n can be used as abstracted in Table-6. A plot 
between log of Mt/Mα against log of time will be linear if the release obeys Peppas 
and Korsemeyer equation and the slope of this plot represents “n” value. 
 
Table 5: Diffusion exponent and solute release mechanism for cylindrical shape  
Diffusion Exponent Overall solute diffusion mechanism 
0.45 Fickian diffusion 
0.45<n<0.89 Anomalous (non-fickian) diffusion 
0.89 Case II transport 
n>0.89 Super Case II transport 
 
4.8 STABILITY STUDIES46, 47 
4.8.1. Introduction 
The purpose of stability testing is to provide evidence on how the quality of an active 
substance or pharmaceutical product varies with time under the influence of a variety 
of environmental factors such as temperature, humidity, and light. In addition, 
product-related factors influence the stability, e.g. the chemical and physical 
properties of the active substance and the pharmaceutical excipients, the dosage form 
and its composition, the manufacturing process, the nature of the container-closure 
system, and the properties of the packaging materials. Also, the stability of excipients 
that may contain or form reactive degradation products, have to be considered. 
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Table- 6: Objectives of Stability Testing: 
OBJECTIVE TYPE OF STUDY USE 
To select adequate (from the 
viewpoint of stability) 
formulations and container-
closure systems 
Accelerated 
Development of the 
product 
To determine shelf-life and 
storage conditions 
Accelerated and 
real-time 
Development of the 
product and of the 
registration dossier 
To substantiate the claimed shelf-
life 
Real-time Registration dossier 
To verify that no changes have 
been introduced in the 
formulation or manufacturing 
process that can adversely affect 
the stability of the product 
Accelerated and 
real- time 
Qeleuality assurance in 
general, including quality 
control. 
 
Climatic Zones and Conditions 
WHO has issued guidelines, where it is stated that the world is divided into four zones 
based on the prevailing annual climatic conditions for the purpose of stability testing. 
Zone I: temperate 
Zone II: subtropical with possible high humidity 
Zone III: hot/dry 
Zone IV: hot/humid 
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Table-7: Mean climatic conditions: measured data in the open air and in the 
storage room 
Climatic 
Zone 
Measured data in the 
Open Air 
Measured data in storage 
room 
oC %RH oC %RH 
 
I 
II 
III 
IV 
 
10.9 
17.0 
24.4 
26.5 
 
75 
70 
39 
77 
 
18.7 
21.1 
26.0 
28.4 
 
45 
52 
54 
70 
 
So for example if a manufacturer plans to sell his products in zone-III he/she should 
do real time studies at 30oC and 35%RH.If a manufacturer wants to apply for the 
registration of a new drug, i.e. if he is applying for a (1) Investigative New Drug 
Application (IND) or (2) New Drug Application (NDA) or (3) Abbreviated New Drug 
Application (ANDA) then he has to assure the FDA regarding the drug’s/drug 
product’s safety, quality and efficacy. For this he has to carry out stability tests and 
submit stability data. How he should do this is specified by Q1A (R2). 
 
4.8.2 Selection of Batches 
Data from formal stability studies should be provided on at least three primary 
batches of the drug substance. These batches should be made to a minimum of pilot 
scale by the same synthetic route as that of the production batches. 
Specifications which include testing methods and acceptance criteria should be fixed. 
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Testing frequency  Months 
Long term:    0, 3, 6, 9, 12, 18, 24 
Accelerated storage:   0, 3, 6 
Storage conditions recommended 
Table-8 : Testing frequency for different storage conditions 
Study Storage condition Minimum time period 
covered by data at 
submission 
Long term* 250C + 20C/60% RH + 5% RH or 
300C + 20C/65% RH + 5% RH 
12 months 
Intermediate** 300C + 20C/65% RH + 5% RH 6 months 
Accelerated 400C + 20C/75% RH + 5% RH 6 months 
* It is up to the applicant to decide whether long term stability studies are performed 
at 25 + 2oC/60% RH + 5% RH or 30 0C + 2oC/65% RH + 5% RH.  
** If 30oC + 2oC/65% RH + 5% RH is the long-term condition, there is no 
intermediate condition.  
If long-term studies are conducted at 25oC+ 2oC/60% RH + 5% RH and “significant 
change” occurs at any time during 6 months’ testing at the accelerated storage 
condition, additional testing at the intermediate storage condition should be conducted 
and evaluated against significant change criteria (ICH, 2003) 
“Significant change” for a drug substance is defined as failure to meet is specification. 
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Table -9 : Drug substances intended for storage in a refrigerator 
  Study Storage condition 
Minimum time period 
covered by data at 
submission 
Long term 50C + 30C 12 months 
Accelerated 250C + 20C/60% RH + 5% RH 6 months 
 
Table-10 : Drug substances intended for storage in a freezer 
Study Storage condition 
Minimum time period covered 
by data at submission 
Long term 200C + 50C 12 months 
 
4.8.3 Stability Testing for Established Drug Substances 
WHO has issued guidelines for stability testing of pharmaceutical products containing 
well established drug substances in conventional dosage form. The stability of 
finished pharmaceutical products depends on environmental factors and on product 
related factors. So stability considerations should be given, the highest priority in the 
design and formulation of a product. The shelf life should be established with due 
regard to the climatic zones. To ensure both patient safety and the rational 
management of drug supplies, it is important that the expiry date and storage 
conditions are properly indicated on the label. 
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4.8.4 Accelerated stability testing 
These are the studies designed to increase the rate of chemical degradation and 
physical change of a drug by using exaggerated storage conditions as part of the 
formal stability testing programme. The data thus obtained, in addition to those 
derived from real – time stability studies, may be used to assess longer – term 
chemical effects under non-accelerated conditions and to evaluate the impact of short-
term excursions outside the label storage conditions, as might occur during shipping. 
The results of accelerated testing studies are not always predictive of physical 
changes. These are also known as stress testing studies. 
 
4.8.5 Expiry date 
The date given on the individual container of a drug product up to and including 
which the product is expected to remain within specifications if stored correctly. It is 
established for each batch by adding the shelf-life period to the date of manufacture. 
 
4.8.6 Real time (Long term) stability studies 
Experiments on the physical, chemical, biological, biopharmaceutical and 
microbiological characteristics of a drug, during and beyond the expected shelf life 
and storage periods of samples under the storage conditions expected in the intended 
market. The results are used to establish the shelf life, to confirm the projected shelf 
life and to recommend storage conditions. 
 
4.8.7 Stability tests 
A series of tests designed to obtain information on the stability of a pharmaceutical 
product in order to define its shelf-life and utilization period under specified 
packaging and storage conditions. The following table gives the main objectives and 
uses the different types of stability testing (ICH, 1995) 
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5. RESULTS & DISCUSSION 
TABLE -11 : DRUG–EXCIPIENTS COMPATIBILITY STUDIES 
 
S.NO EXCIPIENTS RATIO 
DESCRIPTION 
 
Initial Final 
 
 
1 
 
 
 
Losartan potassium – API 
 
 
 
1:1 
 
 
 
White to off 
white 
powder 
 
 
White to off 
white 
powder 
 
2 
 
 
 
 
 
API – Lactose 
 
 
 
 
1:1 
 
 
 
 
Off white 
coloured 
powder 
 
 
Off white 
coloured 
powder 
3 
 
 
 
 
 
API – Microcrystalline 
cellulose 
 
 
 
 
1:1 
 
 
 
 
Off white 
coloured 
powder 
 
 
Off white 
coloured 
powder 
 
 
4 
 
 
 
 
 
 
API – Aerosil 200 
 
 
 
 
 
 1:1 
 
 
 
 
Off white 
coloured 
powder 
 
 
 
Off white 
coloured 
powder 
 
 
 
5 
 
 
         API – Magnesium     
stearate          1:1 
Off white 
coloured 
powder 
Off white 
coloured 
powder 
 
6         API – starch 1500          1:1 
Off white 
coloured 
powder 
Off white 
coloured 
powder 
7         API – HCTZ          1:1 
Off white 
coloured 
powder 
Off white 
coloured 
powder 
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TABLE 12 :     API RESULTS: 
 
 
 
 
 
 
TABLE -13 : BULK DENSITY, COMPRESSIBILITY INDEX, HAUSNER’S 
RATIO, ANGLE OF REPOSE OF LOSARTAN/HCTZ BLEND 
BULK 
DENSITY 
gm/ml 
TAPPED 
DENSITY 
gm/ml 
CARR’S 
INDEX 
(%) 
HAUSNER’S 
RATIO 
ANGLE OF 
REPOSE 
(Ө) 
 
0.362 
 
0.612 42 1.64 30.1 
 
S.N
O 
 
FORMULA
TION          
CODE 
BULK 
DENSITY(g/ml) 
 
 
COMPRESSIBI
LITY INDEX 
(%) 
 
HAUSNE
R’S 
RATIO 
 
ANGLE 
OF 
REPOSE 
(DEGRE
ES) 
Untap
ped 
Tap
ped 
1 
 
F1 
 
0.382 
 
0.439 
 
34.46 
 
1.56 
 
25.0 
 
2 
 
F2 
 
0.410 
 
0.461 
 
36.39 
 
1.59 
 
28.6 
 
3 
 
F3 
 
0.428 
 
0.486 
 
38.43 
 
1.62 
 
29.3 
 
4 
 
F4 
 
0.431 
 
0.457 
 
44.6 
 
1.72 
 
28.6 
 
5 
 
F5 
 
0.426 
 
0.460 
 
40.35 
 
1.65 
 
30.5 
 
6 
 
F6 
 
0.412 
 
0.491 
 
41.8 
 
1.67 
 
32.6 
 
7 
 
F7 
 
0.391 
 
0.445 
 
40.17 
 
1.65 
 
29.1 
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TABLE-14 :  HARDNESS OF LOSARTAN And HCTZ TABLETS FOR 
DIFFERENT FORMULATIONS 
 
 
 
  
 
 
 
 
 
 
       Specifications : 4 – 8 kp 
 
 
 
FIG - 6: HARDNESS OF LOSARTAN And HCTZ TABLETS FOR DIFFERENT 
FORMULATIONS 
 
S.NO FORMULATION     CODE 
HARDNESS OF 
TABLETS(KP) 
1 F1 4.18 
 
2 F2 4.28 
 
3 F3 4.35 
 
4 F4 4.42 
 
5 F5 4.90 
 
6 F6 5.76 
 
7 F7 6.48 
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TABLE -15 THICKNESS OF LOSARTAN And HCTZ TABLETS FOR 
DIFFERENT FORMULATIONS 
 
 
 
 
 
 
 
 
 
specification 4.20+/- 0.3 
 
 
FIG - 7  : THICKNESS OF LOSARTAN And HCTZ TABLETS FOR           
DIFFERENT FORMULATIONS 
 
 
 
S.NO FORMULATION     CODE 
THICKNESS OF 
TABLETS(mm) 
1 F1 4.45 
 
2 F2             4.43 
 
3 F3 4.40 
 
4 F4 4.41 
 
5 F5 4.43 
 
6 F6 4.41 
 
7 F7 4.42 
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TABLE -16 FRIABILITY OF LOSARTAN And HCTZ TABLETS FOR 
DIFFERENT FORMULATIONS 
 
 
 
Specifications : Less than 0.8% 
 
FIG - 8: FRIABILITY OF LOSARTAN and HCTZ TABLETS FOR 
DIFFERENT FORMULATIONS 
 
 
 
 
S.NO FORMULATION     CODE 
FRIABILITY OF 
TABLETS (%) 
1 F1 0.400 
 
2 F2 0.286 
 
3 F3 0.467 
 
4 F4 0.466 
 
5 F5 0.525 
 
6 F6 0.458 
 
7 F7 0.393 
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TABLE - 17 AVERAGE WEIGHT OF LOSARTAN And HCTZ TABLETS FOR 
DIFFERENT FORMULATIONS 
 
 
 
 
 
 
 
 
 
 
      Specifications : 309.00 +/- 2.0% 
         (302.82 – 315.18) 
   
 
FIG - 9: AVERAGE WEIGHT OF LOSARTAN And HCTZ TABLETS FOR 
DIFFERENT FORMULATIONS 
 
 
S.NO FORMULATION     CODE 
AVERAGE 
WEIGHT OF 
TABLETS (mg) 
1 
 
F1 
 
314.0 
 
2 
 
F2 
 
313.5 
3 
 
F3 
 
302.6 
 
4 
 
F4 
 
309.6 
 
5 
 
F5 
 
308.6 
 
6 
 
F6 
 
306.2 
 
7 
 
F7 
 
311.8 
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TABLE - 18 DISINTEGRATION TIME OF LOSARTAN And HCTZ TABLETS 
FOR DIFFERENT FORMULATIONS 
 
 
 
 
 
 
 
 
 
 
       Specifications :Not more than 20 
   
 
FIG - 10: DISINTEGRATION OF LOSARTAN And HCTZ TABLETS FOR 
DIFFERENT FORMULATIONS 
 
S.NO FORMULATION     CODE 
DISINTEGRATION 
OF TABLETS (min) 
1 
 
F1 
 
22.50 
 
2 
 
F2 
 
20.03 
 
3 
 
F3 
 
19.11 
 
4 
 
F4 
 
13.55 
 
5 
 
F5 
 
12.85 
 
6 
 
F6 
 
11.52 
 
7 
 
F7 
 
11.25 
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Table – 19 : INVITRO DISSOLUTION PROFILE OF FORMULATION F1 IN 
PHOSPATE BUFFER MEDIUM 
 
Slno Tablet 
weight(mg) 5 Min 10Min 15Min 20Min 30Min 45Min 
1 308.2 26 35 48 59 72 85 
2 311.4 31 42 58 62 75 88 
3 314.1 34 49 61 72 79 84 
4 316.4 25 35 51 63 75 82 
5 312.1 22 34 46 59 71 80 
6 309.1 28 39 48 61 75 89 
Mean 311.8 28 39 52 63 74 85 
SD - 1.18 1.55 0.90 0.62 1.17 2.36 
 
 
Fig no - 11 INVITRO DISSOLUTION PROFILE OF FORMULATION F1 IN 
PHOSPATE BUFFER MEDIUM 
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Table – 20 : INVITRO DISSOLUTION PROFILE OF FORMULATION F2 IN 
PHOSPATE BUFFER MEDIUM 
Slno Tablet 
weight(mg) 5 Min 10Min 15Min 20Min 30Min 45Min 
1 304.2 15 38 64 75 82 89 
2 311.2 17 41 68 79 84 92 
3 299.8 21 45 69 75 86 94 
4 302.9 16 37 59 72 84 91 
5 314.3 23 42 63 78 86 93 
6 305.2 19 40 62 76 83 95 
Mean 306.2 18 40 64 76 84 92 
SD - 1.18 1.55 0.90 0.62 1.17 2.36 
 
 
Fig no- 12 : INVITRO DISSOLUTION PROFILE OF FORMULATION F2 IN 
PHOSPATE BUFFER MEDIUM 
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Table – 21 : INVITRO DISSOLUTION PROFILE OF FORMULATION F3 IN 
PHOSPATE BUFFER MEDIUM 
Slno Tablet 
weight(mg) 5 Min 10Min 15Min 20Min 30Min 45Min 
1 304.1 20 47 71 84 95 96 
2 312.0 36 68 86 96 102 102 
3 314.6 33 55 73 87 95 97 
4 305.4 34 64 88 97 98 98 
5 310.9 37 65 82 94 96 97 
6 304.8 36 65 81 91 100 102 
Mean 308.6 33 61 80 92 98 99 
SD 0 1.18 1.55 0.90 0.62 1.17 2.36 
 
 
Fig no.-13: INVITRO DISSOLUTION PROFILE OF FORMULATION F3 IN 
PHOSPATE BUFFER MEDIUM 
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Table – 22 : INVITRO DISSOLUTION PROFILE OF FORMULATION F4 IN 
PHOSPATE BUFFER MEDIUM 
Slno Tablet 
weight(mg) 5 Min 10Min 15Min 20Min 30Min 45Min 
1 312.9 14 32 58 76 92 95 
2 309.3 24 52 69 83 95 96 
3 306.0 10 32 50 66 84 91 
4 310.8 19 48 64 73 83 91 
5 309.1 19 47 64 76 88 93 
6 309.2 26 52 72 82 94 96 
MEAN 309.6 19 45 63 76 89 94 
SD 0 1.18 1.55 0.90 0.62 1.17 2.36 
 
 
Fig no- 14 : INVITRO DISSOLUTION PROFILE OF FORMULATION F4 IN 
PHOSPATE BUFFER MEDIUM 
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Table – 23 : INVITRO DISSOLUTION PROFILE OF FORMULATION F5 IN 
PHOSPATE BUFFER MEDIUM 
Slno Tablet 
weight(mg) 5 Min 10Min 15Min 20Min 30Min 45Min 
1 304.2 25 58 74 84 92 94 
2 299.7 33 57 73 82 93 97 
3 304.2 32 59 75 85 93 94 
4 299.8 35 61 80 89 95 95 
5 302.9 43 67 83 90 92 92 
6 304.5 30 56 74 84 93 94 
Mean 302.6 33 60 77 85 93 94 
SD 0 1.18 1.55 0.90 0.62 1.17 2.36 
 
 
Fig no.- 15 : INVITRO DISSOLUTION PROFILE OF FORMULATION F5 IN 
PHOSPATE BUFFER MEDIUM 
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Table – 24 : INVITRO DISSOLUTION PROFILE OF FORMULATION F6 IN 
PHOSPATE BUFFER MEDIUM 
Slno Tablet 
weight(mg) 5 Min 10Min 15Min 20Min 30Min 45Min 
1 308.9 23 51 68 79 92 94 
2 315.0 19 45 66 77 93 95 
3 311.7 29 53 74 86 96 97 
4 313.1 24 47 67 78 91 96 
5 314.9 26 53 68 78 90 94 
6 317.4 21 49 67 78 93 95 
Mean 313.5 24 50 68 79 93 95 
SD 0 1.18 1.55 0.90 0.62 1.17 2.36 
 
 
Fig no.-16 : INVITRO DISSOLUTION PROFILE OF FORMULATION F6 IN 
PHOSPATE BUFFER MEDIUM 
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Table -25 : INVITRO DISSOLUTION PROFILE OF FORMULATION F7 IN 
PHOSPATE BUFFER MEDIUM 
Slno Tablet 
weight(mg) 5 Min 10Min 15Min 20Min 30Min 45Min 
1 317.8 18 44 69 83 99 99 
2 314.4 21 48 68 88 97 99 
3 311.4 19 44 64 79 92 95 
4 318.1 21 46 70 87 98 99 
5 312.7 18 39 63 78 93 95 
6 309.3 25 49 72 85 93 97 
MEAN 314.0 20 45 68 83 95 97 
SD 0 1.18 1.55 0.90 0.62 1.17 2.36 
 
 
Fig no. -17 : INVITRO DISSOLUTION PROFILE OF FORMULATION F7 IN 
PHOSPATE BUFFER MEDIUM 
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Table -26 : INVITRO DISSOLUTION PROFILE OF INNOVATOR IN 
PHOSPATE BUFFER MEDIUM 
Sl.no. 5min 10min 15min 20min 30min 45min 
1 18 44 65 81 95 98 
2 17 45 67 84 98 99 
3 19 45 69 85 92 95 
4 18 46 64 83 91 94 
5 16 43 71 82 98 99 
6 20 47 72 83 96 97 
Mean 18 46 67 82 95 97 
SD 1.18 1.55 0.90 0.62 1.17 2.36 
 
 
Fig no. -18 : INVITRO DISSOLUTION PROFILE OF INNOVATOR IN 
PHOSPATE BUFFER MEDIUM 
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Fig no. -19 :COMPARISON OF  INVITRO DISSOLUTION PROFILE OF 
INNOVATOR VS OPTIMISED FORMULATION IN PHOSPATE BUFFER 
MEDIUM 
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TABLE -27 : COEFFICIENT CORRELATION (r) VALUES FROM INVITRO 
DISSOLUTION RATE TEST OF LOSARTAN POTASSIUM AND 
HYDROCHLORTHIAZIDE CONVENTIONAL TABLETS 
 
Formulation 
Code 
Zero 
Order 
First 
Order 
Higuchi’s Peppas’s 
F1 0.9037 0.9704 0.9809 0.9769 
F2 0.9541 0.9581 0.9679 0.9885 
F3 0.9888 0.9751 0.9695 0.9882 
F4 0.9689 0.8169 0.9834 0.9913 
F5 0.9277 0.99555 0.9797 0.9568 
F6 0.8330 0.9388 0.9512 0.9160 
F7 0.9308 0.9886 0.9876 0.9459 
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Stability results: 
Table – 28: Percentage Cumulative release of stability studies of optimized 
formulation (F7) at  400C / 75% RH and 500C for 1 month 
 
 Cumulative % drug release 
Time (Min) Initial 500C 400C / 75% RH 
0 0 0 0 
5 20±5.0 19±4.5 19±4.1 
10 45±4.9 44±4.1 43±3.5 
15 68±4.0 67±3.2 67±2.9 
20 83±3.2 82±4.1 82±1.8 
30 95±2.1 95±4.0 94±1.1 
45 97±2.0 96±2.1 95±1.0 
 
 
 
 
       Fig no.-20:  Dissolution profiles of 1 month stability samples at  different   
conditions 
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Table – 29 : Physical evaluation for stability studies of optimized formulations 
 
Parameter Initial 500C 400C / 75% RH 
Color White White White 
Surface Smooth Smooth Smooth 
Thickness 
(mm) 4.40 mm 4.41 mm 4.42 mm 
Hardness (kp) 4.0-6.5 4.0-6.0 4.0-6.0 
Wight (mg) 300 ± 0.11 300 ± 0.76 300 ± 1.89 
Assay 99.12% 98.16% 97.98% 
 
 
 
 
 
AFTER 3 MONTHS : 
 
Table – 30 :  Percentage Cumulative release of stability studies of optimized 
formulation (F7) at 400C / 75% RH and 500C for three months 
 
 Cumulative % drug release 
Time (hr) Initial 500C 400C / 75% RH 
0 0 0 0 
5 20±5.0 19±4.8 18±5.1 
10 45±4.9 44±4.1 42±5.2 
15 68±4.0 67±3.5 66±2.6 
20 83±3.2 82±2.1 81±4.2 
30 95±2.1 94±2.0 93±2.9 
45 97±2.0 95±1.8 94±1.2 
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          Fig no. – 21:  Dissolution profiles of 3 months stability samples at  
different conditions 
 
 
 
Table – 31:  Physical evaluation for stability studies of optimized formulations 
 
Parameter Initial 500C 400C / 75% RH 
Color White White White 
Surface Smooth Smooth Smooth 
Thickness 
(mm) 4.40 mm 4.42 mm 4.42 mm 
Hardness 
(kp) 4.0-6.5 4.0-6.0 4.0-5.5 
Wight (mg) 300 ± 0.11 300 ± 0.76 300 ± 1.89 
Assay 99.12% 98.45% 97.99% 
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Fig no.- 22  Drug content of tablets after 3 months stability studies at different 
condition. 
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7. SUMMARY 
 For the treatment of hypertension losartan potassium and hydrochlorthiazide 
conventional tablets are formulated. The hydrochlorthiazide added to the 
formulation to potentiate the activity of the losartan potassium. 
  
 The drugs are found to be stable and there is no any interaction between these 
two drugs and are producing synergistic activity. Also confirmed that there is 
no interaction between the drug and the excipients as a result of 
incompatibility results in different ratios. 
 
 
 The resulted tablets are evaluated for their hardness, weight variation, 
thickness, friability, disintegration, dissolution etc.., 
 
 In F1 batch the granules are cohesive even after drying for about 20 min. the 
loss on drying greater than 3%. The compressed tablets are evaluated for 
disintegration, the disintegration time in deviating from specifications. 
 
 
 In F2 batch to overcome these problems the binder concentration increased so 
that the agglomerates are decreased than the F1 trial. 
 
 In F3 futher concentration of binder is increased to decrease the moisture 
content present in the final blend. 
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 In F4 the microcrystalline cellulose 101 and 200 are added in various 
concentrations and the amount of starch is futher increased to avoid problems 
like cohesive mass and to obtain LOD less than 3%. 
 In F5 the disintegrant is chaned to low substituted hydroxyl propyl cellulose as 
it is found to be better than the previous and even the binder is increased. 
 
 In F6 the microcrystalline cellulose 101 and 200 are added in equal 
concentration to overcome the cohesive mass. The results are found to 
satisfactory. 
 
 
 Even though the results are satisfactory in F6 the concentration of binder is 
further increased in F7 to obtain the better results and the results are good. 
 
 The tablets from F7 complies all the specifications for the evaluation tests. 
The dissolution profile of F7 batch was complied with the innovator and found 
to be equal with that of innovator. 
 
 
 Then the F7 batch samples are kept for stability studies and are found to be 
good after three months. 
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                         CONCLUSION 
 
 The stable robust quality of losartan potassium and hydrochlorthiazide 
conventional tablets are formulated. The formulated tablets are compared with 
the specifications of the innovator and the optimised formulation complies 
with the specifications. 
 The disintegrant used in the formulation is low substituted hydroxyl propyl 
cellulose which is different from that of the innovator and even the binder 
differs from the innovator even though the specifications of the evaluation are 
complied as per the specifications. 
 The optimised formulation is kept for stability studies and the results are good 
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